Introduction {#s1}
============

The totipotent mammalian zygote has the self-organising capacity of generating embryonic and extraembryonic structures to build a complete organism ([@bib81]). This undifferentiated cell will proliferate and its descendants will take lineage decisions that entail a progressive loss of potency. The first differentiation event that leads to distinct lineages takes place during preimplantation development at the morula to blastocyst transition, resulting in the formation of the trophectoderm (TE, extraembryonic population) and the inner cell mass (ICM, that gives raise to the embryonic population and the extraembryonic yolk sac endoderm). How the establishment of these early lineages is achieved has been widely studied and we now know that a combination of morphogenetic cues breaks the symmetry in the embryo ([@bib9]; [@bib48]; [@bib68]). The first morphological sign of differentiation is evident in the compacting morula, 2.5 days after fertilization (embryonic day E2.5), when blastomeres increase their intercellular interactions and outer cells acquire an apical-basal polarity. These polarized cells on the surface enclose an inner group of apolar cells ([@bib31]; [@bib94]). The outer versus inner position of the blastomeres correlates with their fate, becoming TE or ICM respectively, although cells can change their position within the embryo ([@bib1]; [@bib71]; [@bib79]). Prior to compaction, blastomeres appear morphologically equivalent. However, transcriptional differences among blastomeres have been described as early as in the 4 cell embryo ([@bib4]; [@bib15]; [@bib73]). Although cells at this stage are not committed to a specific fate, these early heterogeneities correlate with specific fate biases before lineage commitment. However, how these early heterogeneities arise and their implications in cell plasticity are still unclear ([@bib7]).

Once the embryo compacts, differences in cell membrane contractility and the activity of signalling pathways orchestrate the lineage-commitment of cell populations ([@bib36]; [@bib37]; [@bib44]; [@bib49]; [@bib52]; [@bib53]; [@bib64]). The initial stochastic expression of the main lineage-specific transcription factors (such as CDX2 or GATA3 for the TE, and OCT4 or NANOG for the ICM) is gradually restricted to their definitive domains ([@bib11]; [@bib59]). The Hippo pathway has been shown to act as a readout of cell polarity and therefore, differential intercellular distribution of its components and thus differential activity in polar or apolar cells, will dictate fate ([@bib8]; [@bib24]; [@bib39]; [@bib82]). In outer cells, the pathway is switched off and the transcriptional coactivator YAP is translocated to the nucleus where it will interact with TEAD4, the effector of the pathway, to promote the expression of key TE genes such as *Cdx2* and *Gata3* ([@bib52]; [@bib61]). We have previously shown that Notch signalling also has a role in the regulation of *Cdx2*. It is specifically active in the TE, where the intracellular domain of the Notch receptor (NICD) is translocated into the nucleus where it binds to the transcription factor RBPJ to promote target gene expression. Both Notch and Hippo converge on the TEE, an enhancer upstream of *Cdx2* ([@bib64]). YAP/TEAD and NICD/RBPJ transcriptional complexes interact with the chromatin modifier SBNO1 to favour the induction of *Cdx2* ([@bib80]).

Nevertheless, we still do not understand how these two signalling pathways interact to regulate *Cdx2* in the embryo, if there is crosstalk between them, if they are acting in parallel during development or otherwise. Furthermore, Notch signalling could have other unexplored roles at early stages of mouse development. In this study, we show that Hippo and Notch pathways are largely independent, but that Notch is active earlier, before compaction, and that differences in Notch levels contribute to cell fate acquisition in the blastocyst. Single-embryo RNA-seq points at repressors that block early naïve pluripotency markers as Notch targets. We propose that Notch coordinates the triggering of initial differentiation events within the embryo and regulates the early specification of the trophectoderm.

Results {#s2}
=======

CDX2 expression in the morula is dependent on the Notch and Hippo signalling pathways {#s2-1}
-------------------------------------------------------------------------------------

Previously, we have described how Notch and Hippo pathways converge to regulate *Cdx2* expression, and that different allelic combinations for *Rbpj* and *Tead4* lead to a significantly reduced expression of CDX2 ([@bib64]). Notably, we failed to recover double mutant embryos at the blastocyst stage (E3.5), suggesting that the lack of both factors caused lethality before the blastocyst stage. We therefore decided to investigate embryos at the earlier morula stage (E2.5), where we recovered double mutant embryos at Mendelian ratios ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). CDX2 levels were apparently lower in *Rbpj^-/-^;Tead4^+/-^* and *Rbpj^+/-^;Tead4^-/-^* morulae, as previously observed in blastocysts ([@bib64]). Interestingly, this effect was exacerbated in double mutant embryos (*Rbpj^-/-^;Tead4^-/-^*) in which we did not detect any CDX2 expression in all embryos of this genotype analysed ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

![CDX2 expression depends on Notch and Hippo inputs.\
(**A**) Maximal projections of confocal images after immunostaining for CDX2 in different combinations of wildtype and mutant alleles for *Rbpj* and *Tead4* at E2.5. Nuclei were stained with DAPI. Number of embryos (n) is indicated. Scale bars, 20 μm. (**B**) Optical sections of confocal images after immunostaining for CDX2 and YAP in the CBF1-VENUS reporter line at morula (upper row) and blastocyst (lower row) stage. Fluorescent VENUS reporter is directly detected. Arrowheads indicate a cell positive for CDX2 and VENUS, but negative for nuclear YAP. Nuclei were stained with DAPI. Scale bars, 20 μm. (**C**) Pairwise correlations of single cell fluorescence intensity levels for CDX2, VENUS and YAP from embryos at early morula (8--16 cells, upper row), late morula (17--32 cells, middle row) and blastocyst (lower row) stage. n = 277 blastomeres from 21 embryos (8--16 cell morulae); n = 211 blastomeres from 12 embryos (17--32 cell morulae); n = 428 blastomeres from six embryos (blastocysts). Person correlation (**R^2^**) is indicated for each correlation. (**D**) Venn diagram showing number of positive cells for CBF1-VENUS, YAP and CDX2 at morula stage. n = 415 blastomeres from 28 morulae.](elife-42930-fig1){#fig1}

Compaction of blastomeres and polarization of outer cells are critical morphological events that take place at the morula stage and are linked to the onset of CDX2 expression ([@bib62]; [@bib83]). We therefore decided to investigate if these processes were affected in double mutant morulae. We examined the expression of E-cadherin and phospho-ERM, as markers of cell-cell adhesion and apical polarity. No differences in the distribution or intensity of these markers was observed in any of the allelic combinations examined, including double mutants for *Rbpj* and *Tead4* ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Therefore, disruption of Notch and Hippo signalling does not alter cellular and morphological events prior to lineage specification, but does result in a dramatic downregulation of *Cdx2* at this stage.

To better understand the contributions of each of the Notch and Hippo pathways to CDX2 expression, we performed correlations in single cells between Notch, YAP and CDX2. We used a transgenic mouse line carrying CBF1-VENUS as a reporter of Notch activity ([@bib56]), and we performed immunostaining to detect YAP and CDX2 in morulae and blastocysts from that reporter line. In the blastocyst, the three markers were restricted to nuclei of the TE, while in the morula their expression was more heterogeneous ([Figure 1B](#fig1){ref-type="fig"}). Nuclear YAP was detected preferentially in outer cells, presumably polarized blastomeres, whereas CBF1-VENUS and CDX2 were detected in both inner and outer cells of the morula. We quantified nuclear intensity levels using a Matlab based segmentation tool, MINS ([@bib42]), and found that CBF1-VENUS and YAP both correlated positively with CDX2 at early morula (8--16 cells), late morula (17--32 cells) and blastocyst stages ([Figure 1C](#fig1){ref-type="fig"}). This correlation was low in the earliest embryos but gradually increased. Interestingly, there was no correlation between CBF1-VENUS and YAP in the early or late morula, suggesting that the two pathways are activated independently at this stage ([Figure 1C](#fig1){ref-type="fig"}). By the blastocyst stage, these markers did show a positive correlation, albeit weaker than the correlation of either marker with CDX2 ([Figure 1C](#fig1){ref-type="fig"}). If all three components were taken into account simultaneously, the coefficient of correlation increases in early and late morulae and blastocyst ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), indicating that the combination of Notch and Hippo pathways better accounted for CDX2 levels than any of them individually.

In most cases, individual nuclei from morulae were positive for the three markers. However, we did find a few cases in which nuclei were positive for CBF1-VENUS and CDX2 but negative for YAP ([Figure 1B](#fig1){ref-type="fig"}, arrowhead). We therefore analysed all morulae to determine the distribution of cells positive for each combination of markers. We found that Notch was active in most of the cells at this stage and that the majority of blastomeres were positive for all three of the markers (295 blastomeres, 72.3%; [Figure 1D](#fig1){ref-type="fig"}). Another noteworthy population was represented by cells that were only positive for CBF1-VENUS and CDX2 (85 blastomeres, 20.8%). However, we rarely found cells expressing YAP and CDX2 but not CBF1-VENUS at the morula stage ([Figure 1D](#fig1){ref-type="fig"}). Together, this set of experiments shows that Notch and Hippo correlate with CDX2 expression at the morula stage, and suggests that they could be acting independently from each other in its regulation.

Absence of crosstalk between the Notch and Hippo signalling pathways in the early mouse embryo {#s2-2}
----------------------------------------------------------------------------------------------

The correlation analysis between CBF1-VENUS and YAP expressing blastomeres indicated possible independent roles for Notch and Hippo in the regulation of CDX2 expression ([Figure 1C](#fig1){ref-type="fig"}). Furthermore, our previous results showed how these two pathways acted in parallel to transcriptionally regulate *Cdx2* through a distal enhancer element ([@bib64]). To further study the interaction between these pathways, we examined TEAD4 and YAP expression in *Rbpj^-/-^* ([Figure 1---figure supplement 3A,B](#fig1s3){ref-type="fig"}) and *Notch1^-/-^* ([Figure 1---figure supplement 3C,D](#fig1s3){ref-type="fig"}) blastocysts. We did not detect any differences in levels or pattern of expression of TEAD4 and YAP either in *Rbpj^-/-^* or in *Notch1^-/-^* embryos as compared to wildtype embryos. We also studied the reverse situation, crossing the CBF1-VENUS mouse line as a reporter of Notch pathway activity into the *Tead4* null background. We detected VENUS fluorescent protein in both wildtype and *Tead4^-/-^* embryos ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Interestingly, CBF1-VENUS expression was maintained in outer cells although the *Tead4^-/-^* embryos do not form a proper blastocyst ([@bib51]), in line with previous results showing that some degree of outer identity still is present in *Tead4^-/-^* embryos ([@bib87]; [@bib51]; [@bib13]). These results confirm that Notch is not required for proper deployment of the transcriptional effectors of the Hippo pathway, and vice versa, that activation of the Notch pathway can occur in embryos deleted for *Tead4*, one of these effectors.

Notch regulates the onset of *Cdx2* expression {#s2-3}
----------------------------------------------

To better understand how parallel signalling pathways drive *Cdx2* expression, we determined if the temporal expression of *Cdx2* was regulated differentially by Notch and Hippo. To do so, we took advantage of pharmacological compounds that allow inhibition of these pathways in a time-controlled manner. We used RO4929097 (RO) to inhibit the Notch pathway ([@bib50]) and Verteporfin to block the YAP-TEAD4 interaction ([@bib41]). We treated wildtype embryos in two different time-windows: from the two-cell up to morula stage, and from morula to blastocyst. As a control, we treated embryos with DMSO, the solvent used for diluting both inhibitors. This was important, as high doses of DMSO result in embryo lethality, what also limits the concentration of inhibitors to be used. We confirmed that treatment with RO in both time-windows was affecting Notch signalling as expected, as it visibly reduced CBF-VENUS activity in embryos ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Efficacy of Verteporfin in interfering with YAP-TEAD4 activity was inferred by its effect on known targets, as we have previously shown in blastocyst for *Cdx2* ([@bib64]). After treatment, gene expression in embryos was analysed by RT-qPCR. In the early time window, from two-cell to morula, we observed that *Cdx2* was downregulated when Notch was inhibited, while there was no change when Hippo pathway activity was altered ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, the opposite was found when we modulated the pathways from the morula onwards. *Cdx2* expression was only affected when YAP-TEAD4 activity was blocked ([Figure 2B](#fig2){ref-type="fig"}). These results show that, although both pathways cooperate in the regulation of *Cdx2*, they act sequentially to regulate *Cdx2* levels in a stage specific manner rather than being redundant. Interestingly, *Gata3*, a known target of YAP-TEAD4 independent of *Cdx2* ([@bib61]) is downregulated by Verteporfin in embryos treated from the two-cell to morula stage ([Figure 1A](#fig1){ref-type="fig"}). This suggests that certainly Hippo signalling acts differently on its various targets, as are *Cdx2* or *Gata3. Oct4* and *Nanog* were not significantly changed after Notch or YAP inhibition in any of the time windows.

![Notch regulates CDX2 in the early morula.\
(**A--B**) Normalised expression of *Cdx2*, *Gata3*, *Oct4* and *Nanog* in pools of 25 embryos treated with RO4929097 to inhibit Notch (left) or with Verteporfin to inhibit YAP/TEAD interaction (right), from the 2 cell to morula stage (A; Notch inhibition, n = 6); YAP/TEAD inhibition, n = 6--9) or from morula to blastocyst stage (B; Notch inhibition, n = 4--6; YAP/TEAD inhibition, n = 6--11). n represents number of unique pools of 25 embryos. Pools of embryos treated with DMSO were used as controls. \* p-value\<0.05 by Student's t test. (**C**) Maximal projections of confocal images after immunostaining of CDX2 in wildtype and *Rbpj^-/-^* early morulae. (**D**) Violin plots of CDX2 intensity levels and (**E**) quantification of number of CDX2 positive cells in wildtype and *Rbpj^-/-^* early morulae (n = 11 embryos). (**F**) Maximal projections of confocal images after immunostaining of CDX2 in wildtype and *Rbpj^-/-^* late morulae. (**G**) Violin plots of CDX2 intensity levels and (**H**) quantification of number of CDX2 positive cells in wildtype and *Rbpj^-/-^* late morulae (wildtype, n = 4 embryos; *Rbpj^-/-^*, n = 5 embryos). Nuclei were stained with DAPI. Scale bar, 20 μm. Data are means ± s.d. \*\*\*p\<0.001 by Student's t test (**D**) or by Fisher's exact test (**E**).](elife-42930-fig2){#fig2}

Next, we wished to confirm these observations in morula stage embryos using genetic loss of function models. We recovered early (8--16 cells) and late (17--32 cells) morulae and analysed CDX2 expression in wildtype and *Rbpj^-/-^* embryos ([Figure 2C--E](#fig2){ref-type="fig"}). We found that *Rbpj^-/-^* early morulae had a significantly lower level of nuclear CDX2 expression ([Figure 2D](#fig2){ref-type="fig"}) and number of CDX2 positive cells compared to control littermates ([Figure 2E](#fig2){ref-type="fig"}). In contrast, we did not observe differences at the late morula stage ([Figure 2F--H](#fig2){ref-type="fig"}). The same observations were obtained when we analysed embryos from another mutant for the pathway, *Notch1^-/-^*: early morulae (8--16 cells) showed lower CDX2 expression and a decrease in the number of CDX2 positive cells ([Figure 2---figure supplement 1A--C](#fig2s1){ref-type="fig"}), but late (17--32 cells) morulae did not ([Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}). This result is interesting, as it suggests that *Notch1* is the main receptor acting upstream of RBPJ during preimplantation development as its loss is enough to recapitulate *Rbpj* loss of function effects.

These results indicate that there is an earlier requirement for Notch than for Hippo in the regulation of *Cdx2*, and that both pathways exert non-redundant roles. Our observations are suggestive of a model where Notch regulates the onset of *Cdx2* expression, and the Hippo pathway subsequently maintains its expression.

The Notch pathway is heterogeneously active in the embryo starting at the 4-cell stage {#s2-4}
--------------------------------------------------------------------------------------

In light of the above findings revealing a requirement of the Notch pathway for the early stages of mouse preimplantation development, we decided to investigate when Notch is first active, using the CBF1-VENUS reporter line as a transcriptional readout of the pathway. We recovered embryos from the CBF1-VENUS line and found that the reporter was first active in 4 cell embryos, albeit at lower levels than at later stages ([Figure 3A](#fig3){ref-type="fig"}). The number of VENUS positive cells was variable among embryos, with at least a third of embryos examined having no positive cells (7 out of 20; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This strongly suggests that the onset of Notch pathway activation is indeed occurring at this stage. As a general rule, the number of positive blastomeres increased with the total number of cells per embryo ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In the compacted morula, most of the cells were positive, but the activity of the reporter was quickly restricted to the outer TE cells once the blastocyst formed ([Figure 1B](#fig1){ref-type="fig"}).

![CBF1-VENUS dynamics in the mouse preimplantation embryo.\
(**A**) Maximal projections of confocal images of CBF1-VENUS reporter line in 4 cell, 6 cell, 8 cell and compacted morula stages. A white and a grey arrowhead respectively indicate a positive and a negative cell for VENUS in a 4 cell embryo. Immunostaining of pERM (bottom row) confirms acquisition of apical polarity in compacted morulae. Nuclei were stained with DAPI. Scale bar, 20 μm. (**B**) Percentage of VENUS positive cells per embryo at different stages (4--5 cell embryos, n = 24; 6--7 cell embryos, n = 7; 8 cell embryos, n = 9). (**C**) Maximal projections of four time-frames during live imaging of embryos from the CBF1-VENUS reporter line. Time since the onset of time lapse is indicated. (**D**) 3D reconstruction of the time-lapse imaging of a representative embryo. A selected cell and its progeny are highlighted in orange. Blue blastomeres indicate inner position and gray blastomeres indicate outer position. (**E**) Mean intensity levels of VENUS in all the families of the live imaged embryos (n = 7) according to the position of a cell and their progeny in the first and the last time frame. (**F**) Initial intensity levels of VENUS in all the families of the live imaged embryos according to the position of a cell and their progeny in the first and the last time frame. For (**E**) and (**F**), n = 13 families for IN-ICM, n = 11 families for IN--TE + ICM, n = 55 families for OUT TE, n = 16 families for OUT--TE + ICM. \*\*\*p\<0.001, \*p\<0.05 by ANOVA with Bonferroni post-test.](elife-42930-fig3){#fig3}

In order to follow the dynamics of the reporter and determine how restriction of Notch activity is achieved during development, we performed live imaging for up to 24 hr of embryos from the compacted morula (16 cell) to the early blastocyst stage ([Video 1](#video1){ref-type="video"}, [Figure 3C](#fig3){ref-type="fig"}). After tracking of the cells in each embryo (n = 7; [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), we used a Matlab based tool to analyse the behaviour of each individual cell and its progeny within the embryo. With this tool, we were able to reconstruct the embryo in each time point and assign an initial position (inner or outer) to each blastomere as well as its final location in the TE/out or the ICM/in ([Video 2](#video2){ref-type="video"}, [Figure 3D](#fig3){ref-type="fig"}). We first generated a lineage tree so that each lineage or family includes a cell in the time frame 0 and all their descendant cells. We next classified families according to the position of the cells in the first and final time points. This allowed us to divide the cells in four groups: 'IN-ICM' (cells that began in an inner position and their descendants remained in an inner position), 'IN-TE +ICM' (cells that began in an inner position and at least one of their descendants ended up in an inner position but other/s in an outer position), 'OUT-TE' (cells that began in an outer position and their descendants remained in an outer position), and 'OUT-TE +ICM' (cells that began in an outer position and at least one of their descendants ended up in an outer position but other/s ended up in an inner position).

###### Time lapse imaging of a mouse embryo from the CBF1-VENUS line during morula to blastocyst transition.

10.7554/eLife.42930.014

###### 3D reconstruction of a mouse embryo from the CBF1-VENUS line after live imaging during morula to blastocyst transition.

10.7554/eLife.42930.015

Confirming previous findings ([@bib1]; [@bib46]; [@bib59]; [@bib76]; [@bib79]), although most of the cells of the blastocyst retain the position of their predecessor cell in the compacted morula, a small percentage change their location ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). We next measured intensity levels of the reporter in all cells within families, and determined if it correlated with their position during the time lapse. Notch activity levels were variable among families and embryos, but we detected higher and increasing levels in OUT-TE families while IN-ICM families generally showed lower and decreasing levels ([Figure 3---figure supplement 2C--D](#fig3s2){ref-type="fig"}). The intensity levels in families that contributed both inner and outer cells did not follow a clear pattern ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). When we analysed the mean intensity for each group, we saw that VENUS levels were significantly lower in the families that were always inside as compared to the families that were always outside ([Figure 3E](#fig3){ref-type="fig"}). Interestingly, this difference was already manifest when we measured the initial intensity in the first time point ([Figure 3F](#fig3){ref-type="fig"}). In the families whose cells end up in both inner and outer position, VENUS levels were intermediate ([Figure 3E,F](#fig3){ref-type="fig"}).

Therefore, the analysis of the CBF1-VENUS line showed that the reporter is active before the first lineage decision is taken, and that differences in the levels of pathway activation in inner or outer cells of the compacted morula correlate with the final position of their descendants in the blastocyst.

Different Notch levels influences cell position in the morula and the blastocyst {#s2-5}
--------------------------------------------------------------------------------

We have previously shown that increasing the activity of the Notch signalling pathway leads to a preferential allocation of cells to the outer trophectoderm of the blastocyst ([@bib64]). However, we had not tested the onset of this effect and whether blocking Notch would have an effect in early embryos. To address these questions, we used a genetic mosaic line (iChr‐Notch‐Mosaic) that allowed us to generate cells with different Notch activity levels within the same embryo ([@bib58]). The construct consists of three different cassettes preceded by a specific LoxP site. The first cassette is a H2B-CHERRY fluorescent protein and generates wildtype cells. The second cassette contains a dominant-negative version of *Mastermind-like 1* (DN-MAML1), a transcriptional co-activator of the Notch pathway, linked to a H2B-eGFP by a cleavable 2A peptide, whose expression leads to the loss of function (LOF) of the pathway, while the third is a gain of function (GOF) cassette through the expression of a constitutively active NICD linked to an HA-H2B-Cerulean ([Figure 4A](#fig4){ref-type="fig"}). The specific LoxP sites are mutually exclusive, so in any unique cell there will be only one possible outcome as the result of Cre-mediated recombination. We used a Polr2a^CreERT2^ driver which is ubiquitously expressed and inducible by tamoxifen ([@bib18]). We induced recombination by adding 4OH-Tx (4-hydroxy-tamoxifen) from the 2- to the 4-cell stage, aiming to achieve a situation where cells expressing each cassette derive from a single recombined blastomere, and we evaluated recombination in the late morula (\<32 cells) or in the blastocyst ([Figure 4A](#fig4){ref-type="fig"}). We performed immunofluorescent assays with three antibodies to distinguish the three cassettes. The wildtype cassette was detected by an anti-RFP antibody, the LOF by an anti-GFP antibody, and the GOF an anti-HA antibody. However, GOF cells were triple positive because of cross-reactivity between antibodies and the HA-H2B-Cerulean protein ([Figure 4A,B](#fig4){ref-type="fig"}). To validate this strategy, we induced recombination in a iChr‐Notch‐Mosaic ES cell line, and sorted cells according to their fluorescence. Testing the antibodies described above in these populations confirmed that they correctly identified cells derived from each different recombination event ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Confirmation that we were modifying Notch signalling as predicted with the LOF and GOF cassettes came from analysing nuclear CDX2 levels, as a readout of Notch activity. Notch LOF blastomeres showed lower CDX2 levels than wildtype and GOF, and these higher levels than wildtypes ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

![Differences in Notch activity drive cell fate in the preimplantation embryo.\
(**A**) Schematic diagram of the experimental strategy, where iChr-Notch-Mosaic mice were crossed with Polr2a^CreERT2^ driver. Embryos were collected and treated with 4OH-Tamoxifen from 2- to 4-cell stage to induce recombination. At morula and blastocyst stage, embryos were fixed and immunostained. (**B**) Optical section of confocal images after immunostaining for RFP, GFP and HA. Arrowheads indicate examples of cells recombined for the wildtype cassette (red), the Notch loss of function cassette (LOF, green) or the Notch gain of function cassette (GOF, blue). Nuclei were stained with DAPI. Scale bars, 20 μm. (**C**) Percentage of not recombined cells or recombined for each cassette in morulae (n = 10) and blastocysts (n = 11). (**D--E**) Percentage of not recombined cells or recombined for each cassette that are in an inner or outer position at the morula (D; not recombined, n = 69; wildtype, n = 33; LOF, n = 29; GOF, n = 83) or blastocyst stage (E; not recombined, n = 190; wildtype, n = 87; LOF, n = 50; GOF, n = 173). \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001 in relation to not recombined cells by Chi-square test.](elife-42930-fig4){#fig4}

We selected embryos in which at least two recombination events leading to LOF and GOF cells had occurred, and analysed the percentage of unrecombined cells (36%), and cells expressing the control, LOF or GOF cassette. Although the probabilities of recombination are higher when the LoxP sites are closer to one another (the control recombination event in this case), we found that most of the recombined cells were Notch GOF (36% of total cells) while only a small proportion (11%) were Notch LOF, ([Figure 4C](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2A,B](#fig4s2){ref-type="fig"}). If we used a control line (iChr-Control-Mosaic; [@bib58]) carrying the same construct and reporters but not the LOF or GOF cassettes ([Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}), we observed a similar proportion of unrecombined cells (34%) but in this case the most probable event (red cells) was the most abundant (34%), as expected ([Figure 4---figure supplement 3B](#fig4s3){ref-type="fig"}). These results suggest that Notch activity could differentially affect cell proliferation or cell loss in the embryo.

Next, we determined the proportion of cells from each population that were in an inner or outer position. Approximately 60% of unrecombined or wild type (red) cells, both being controls, were located at outer positions in both morula and blastocyst stage. However, Notch-LOF cells (green) were enriched at inner positons of the morula or more clearly in the inner cell mas of the blastocyst, while Notch-GOF cells (blue) tended to occupy outer positions ([Figure 4D,E](#fig4){ref-type="fig"}). These differences were not observed when we analysed embryos from the iChr-Control-Mosaic line ([Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}). These experiments show how manipulating levels of Notch pathway activity as early as the 4-cell stage instructs cells to adopt an inner or outer position at later stages.

Lack of *Rbpj* represses *Tle4* and *Tbx3*, and disrupts the triggering of differentiation programs in the early embryo {#s2-6}
-----------------------------------------------------------------------------------------------------------------------

Results described above show that the Notch pathway plays an early role in mouse development, non-redundant with that of the Hippo pathway, in regulating *Cdx2* gene expression and in determining the position of cells to inner or outer locations. To gain further insight into how Notch is acting during preimplantation development, we carried out RNA-sequencing (RNA-seq) in control and *Rbpj^-/-^* single morulae. 2028 genes were differentially expressed ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), close to 70% of which were downregulated suggesting that *Rbpj* is mainly activating gene expression at the morula stage.

Among the downregulated genes we found *Cdx2* and other TE associated genes such as *Gata3* or *Fgfr2* ([@bib21]; [@bib27]; [@bib26]; [@bib61]); genes related with the Hippo pathway (*Nf2*, *Amotl2*, *Lats2*) and, interestingly, also genes related with the embryonic pluripotency network including *Sall1*, *Sall4, Tbx3* or *Sox21* ([@bib15]; [@bib22]; [@bib33]; [@bib54]; [@bib90]) ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Among the upregulated genes, we found *Dppa3* (*Stella*) and *Prdm14*, which have been characterised as naïve pluripotency markers([@bib23]; [@bib89]). In addition, a large set of chromatin modifiers were differentially expressed ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Important chromatin dynamics have been reported during preimplantation development ([@bib5]), which could fit in with the broad mis-regulation of transcription in the mutant embryos. Remarkably, some of the downregulated modifiers like *Dnmt3b* or *Kdm6a* have been shown to be enriched in TE conversely to *Prdm14* ([@bib4]). Overall, the transcriptome profiling suggests that embryos lacking *Rbpj* do not properly trigger trophectoderm differentiation programs, and that they also affect pluripotency related genes.

![*Tle4* is a direct transcriptional target of Notch.\
(**A**) Volcano plot of differentially expressed genes between wildtype and *Rbpj^-/-^* single morulae. In blue, genes downregulated in *Rbpj^-/-^* (adj.pvalue \<0.05 and logFC \< −1); in orange, genes upregulated in *Rbpj^-/-^* (adj.pvalue \<0.05 and logFC \>1). Representative genes are indicated. (**B**) Number of differentially expressed genes (DEG) between wildtype and *Rbpj^-/-^* morulae (top), those that have a RBPJ motif in a 10 Kb window surrounding the gene (middle), and those in which this site is included in an open chromatin ATAC-seq peak in 8 cell embryos ([@bib84]) (bottom). (**C**) *Tbx3* and *Tle4* normalised expression in pools of 25 embryos after treatment with RO4929097 to block Notch from 2 cell to morula stage. Pools of embryos treated with DMSO were used as controls (n = 8--10). n represents number of unique pools of 25 embryos. (**D**) Genomic landscape of the region upstream *Tle4* indicating the location of the RBPJ motif and the ATAC-seq track. (**E**) Maximal projection confocal images after RFP immunostaining of representative transgenic embryos for the region highlighted in pink in (**D**) (top) or the mutated version for the RBPJ site (bottom). Nuclei were stained with DAPI. Scale bar, 20 μm. (**F**) Percentage of positive embryos in the transient transgenic assay of Tle4-up region (n = 137) or the mutated version (n = 169). (**G**) *Tle4* normalised expression in single embryos (wildtype, n = 14; mosaic, n = 9; deleted, n = 10) after CRISPR/Cas9 deletion of the region containing the RBPJ motif. Data are means ± s.d. \*p\<0.05 by Student's t test in (**C**) and (**G**). \*\*p\<0.01 by Student's t test in (**G**) or by Fisher's exact test in (**F**).\
10.7554/eLife.42930.023Figure 5---source data 1.Table with differentially expressed genes (DEG) obtained after the RNA-seq analysis in control and *Rbpj* mutant morulae.\
10.7554/eLife.42930.024Figure 5---source data 2.Table with differentially expressed genes (DEG) that have an RBPJ consensus binding site included in an open chromatin ATAC-seq peak in a 10 Kb window surrounding the gene.](elife-42930-fig5){#fig5}

To identify direct targets of Notch signalling at this stage, we searched for putative RBPJ binding sites in the vicinity of differentially expressed genes. We established an arbitrary window of 10 Kb surrounding each gene to perform the analysis and found RBPJ binding motifs in 1487 genes. We then examined how many of these putative binding sites were located in regions of open chromatin, a hallmark for active regulatory elements. For this, we took advantage of ATAC-seq profiles from published datasets of 8 cell mouse embryos ([@bib84]), and reduced our list to 282 genes ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). Among these was *Cdx2*, where the predicted RBPJ sites and ATAC-seq open chromatin signature mapped to the TEE enhancer we had previously characterised ([@bib64]), thus validating this approach.

We selected two genes as putative Notch targets, that were downregulated in *Rbpj*^-/-^ morulae and had been previously associated with exit from pluripotency in mouse ES cells: those coding for the Groucho-family transcriptional repressor TLE4 ([@bib38]), and the T-box family transcription factor TBX3 ([@bib66]; [@bib78]). Both genes are heterogeneously expressed in ES cells and repress naïve pluripotency genes. We hypothesized that *Tle4* and *Tbx3* could be direct targets of Notch, and that their downregulation could in part explain the blockade in differentiation that we observe in the RNA-seq. We independently confirmed downregulation of their expression after blocking the Notch pathway by treating wildtype embryos with the RO4929097 inhibitor from 2 cell to morula stage ([Figure 5C](#fig5){ref-type="fig"}).

An RBPJ motif search within ATAC-seq peaks in the vicinity of the genes identified two potential candidate regions located 1.3 Kb upstream of *Tle4* (Tle4-up; [Figure 5D](#fig5){ref-type="fig"}) and in the seventh intron of *Tbx3* (Tbx3-i7; [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}), respectively. By means of transient transgenic assays ([@bib64]), we proved that these regions could act as transcriptional enhancers driving H2B-mRFP reporter expression in the morula (32% positive embryos for the 700 bp Tle4-up element, [Figure 5E,F](#fig5){ref-type="fig"}; and 56% for the 600 bp Tbx3-i7 element; [Figure 5---figure supplement 2B,C](#fig5s2){ref-type="fig"}). To test if Notch was directly involved, we mutated the RBPJ motif inside these regions and found that the activity of the Tle4-up mut^RBPJ^ fragment was significantly diminished (from 32% to 13% positive embryos, [Figure 5E,F](#fig5){ref-type="fig"}) while the Tbx3-i7 mut^RBPJ^ fragment was not affected (60% positive embryos, [Figure 5---figure supplement 2B--C](#fig5s2){ref-type="fig"}). Finally, to examine whether these enhancers were necessary for the expression of their putative target genes, we deleted the regions within the enhancers that contained the RBPJ motif by CRISPR/Cas9 mediated genome editing ([@bib63]), and analysed gene expression by qPCR on individually edited morulae. For this we used two guide-RNAs flanking the regions that contained the putative RBPJ binding site, what generated deletions of approximately 150 bp ([Figure 5---figure supplement 2E,F](#fig5s2){ref-type="fig"}). We observed a significant decrease in *Tle4* expression in edited embryos (deleted, n = 10) as compared to injected embryos that had been partially (mosaic, n = 9) or not (wildtype, n = 14) edited ([Figure 5G](#fig5){ref-type="fig"}). However, *Tbx3* expression did not change when the RBPJ motif from the seventh intron was deleted ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). These assays provide evidence that these genomic regions act as *cis*-regulatory elements and, in the case of *Tle4*, are directly regulated by RBPJ and necessary for correct expression.

Notch levels coordinate the balance between naïve pluripotency and triggering of differentiation in ES cells {#s2-7}
------------------------------------------------------------------------------------------------------------

The transcriptomic profiling carried out in *Rbpj^-/-^* embryos identified genes related with naïve pluripotency among the upregulated genes. Naïve pluripotency corresponds to a state in which cells are not prone to differentiate, in contrast to primed pluripotency ([@bib32]). These pluripotent states as well as the transition between them have been extensively studied in ES cells and EpiLCs, in vitro counterparts of the epiblast of the blastocyst stage preimplantation embryo and the postimplantation pre-gastrulating epiblast respectively ([@bib19]). Interestingly, some of these naïve markers such as *Prdm14* are initially expressed at the 2- and 4-cell stage, switched off in the morula and re-expressed in the ICM of the blastocyst ([@bib4]). Analysis of published single-cell RNA-seq data ([@bib15]) confirmed that *Prdm14* decreased dramatically from the 4- to 8-cell stage, and expression of *Dppa3* also decreases from the 2- to the 4-cell stage ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). In contrast, *Tle4* and *Tbx3* levels increased from the 4- to 8-cell stage ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Our data from *Rbpj^-/-^* morulae suggests that embryos do not switch off *Prdm14* and *Dppa3*, and inhibiting Notch with RO4929097 from the 2- to 4-cell stage confirmed the effect on *Prdm14*, whose levels were significantly increased after the treatment ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

We wondered if the effect of Notch guiding differentiation programs that we had seen in the embryo was also occurring in ES cells. We used iChr-Notch-Mosaic ES cells ([@bib58]) to confront populations with different Notch levels using the same strategy than we had previously used in the embryo ([Figure 6A](#fig6){ref-type="fig"}). After recombination by transfection with *Cre*, ES cells were sorted according to the fluorescent reporter cassette they expressed ([Figure 6B](#fig6){ref-type="fig"}). We measured expression levels of naïve pluripotency markers by qPCR, and found that levels of *Prdm14* and *Dppa3* correlated negatively with Notch activity but other markers such as *Nanog* or *Esrrb* were not altered ([Figure 6C](#fig6){ref-type="fig"}). We next asked how Notch would affect the differentiation potential of pluripotent cells using this system. For that, we allowed sorted iChr-Notch-Mosaic ES cells grown in serum +LIF to differentiate for 48 hr after LIF removal and analysed the expression of genes related to early differentiation at different time points ([Figure 6D](#fig6){ref-type="fig"}). On the one hand, we observed that the peak of expression of *Tle4*, and the early epiblast markers *Fgf5* and *Pou3f1* occurred earlier and remained at higher levels in Notch GOF than in wildtype ES cells. On the other hand, Notch LOF cells never reached normal levels of *Tbx3* or *Fgf5* during the differentiation process ([Figure 6E](#fig6){ref-type="fig"}). These results suggest that Notch is not only sufficient to drive expression of some differentiation markers such as *Tle4*, but also necessary to achieve proper levels of others such as *Tbx3*. However, modulation of Notch levels is not enough to change expression of pluripotency markers once ES cells have started the differentiation process ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). If we carried out the experiment but using ES cells maintained under naïve conditions (2i + LIF), we observed similar dynamics for *Tle4* and *Tbx3* and other early epiblast markers, but no changes in later differentiating genes ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Overall, our results suggest that Notch is involved in coordinating exit from pluripotency and promoting cell differentiation in ES cells, mirroring its role in the early embryo.

![Notch promotes exit from naïve pluripotency and cell differentiation of ES cells.\
(**A**) Construct showing the wildtype (red), Notch loss of function (green) and Notch gain of function (blue) cassettes from iChr-Notch-Mosaic ES cells. (**B**) Schematic diagram of experimental design, where iChr-Notch-Mosaic ES cells were recombined with Cre and sorted according to Notch activity. (**C**) *Prdm14*, *Dppa3*, *Nanog* and *Esrrb* normalised expression in iChr-Notch-Mosaic ESCs after sorting of Notch LOF, wildtype and Notch GOF populations (n = 13 for *Prdm14*, n = 17 for *Dppa3*, n = 16 for *Nanog*, n = 11 for *Esrrb*). (**D**) Schematic diagram of experimental design, where sorted recombined iChr-Notch-Mosaic ES cells were differentiated after LIF removal. (**E**) *Tle4*, *Tbx3*, *Fgf5* and *Pou3f1* normalised expression in Notch LOF, Wildtype and Notch GOF cells at 0 hr, 12 hr, 24 hr and 48 hr after LIF withdrawal (n = 6). Data are means ± s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 in relation to wildtype cells by ANOVA with Fisher post-test.](elife-42930-fig6){#fig6}

Discussion {#s3}
==========

During the first three days of mouse embryonic development, cells lose their totipotent capacity as they form the first differentiated population, the trophectoderm (TE). In this study, we show that Notch signalling regulates the early expression of *Cdx2*, a key element in TE specification, and that this is later reinforced by the input of Hippo signalling through YAP and TEAD4. Hippo has been shown to act as a readout of cell polarity ([@bib1]; [@bib25]) and it activates *Cdx2* in cells that have established an apical domain. However, the initial triggering of *Cdx2* both in inner and outer cells ([@bib11]; [@bib59]) suggested that inputs other than Hippo would initially be acting because its expression could not be explained only by YAP/TEAD4 activity. In fact, previous reports have described that although in most *Tead4^-/-^* blastocysts CDX2 is not detected, earlier *Tead4^-/-^* morulae retain CDX2 expression ([@bib51]). Similarly, double *Wwtr1;Yap1* mutant embryos show some residual CDX2 expression ([@bib13]). In agreement with these observations, we found blastomeres in the morula that express CDX2 but do not have nuclear YAP. In this situation, expression of CDX2 is likely due to Notch activity as the CBF1-VENUS reporter, used as a proxy for activity of the pathway ([@bib56]), is present in those cells. The analysis of *Rbpj* and *Notch1* mutants in early and late morulae, as well as pharmacological treatments of preimplantation embryos, further support the notion that the input provided by Notch is necessary for the early phases of *Cdx2* expression. These results show that Notch and Hippo have non-redundant but partially overlapping roles in early and late phases of *Cdx2* expression, respectively. Furthermore, only double knockout morulae for *Rbpj* and *Tead4* completely lack CDX2, and all CDX2 positive cells have at least one of the two pathways active. These findings support a model whereby overlapping or complementary inputs from different signalling pathways may provide robustness in the system, buffering any disturbances and ensuring proper development ([@bib47]). In such a model, Notch and Hippo would ensure the correct specification and maintenance of the TE respectively ([@bib64]).

The crosstalk between YAP and Notch has been studied in different cellular contexts ([@bib75]). YAP acts upstream of Notch in controlling epidermal stem cell fate or liver cell fate ([@bib74]; [@bib92]) while Notch is upstream of YAP in the corneal epithelium during chronic inflammation ([@bib55]). Also, YAP and Notch can cooperate to control the onset of oscillations in the segmentation clock ([@bib29]) and they interact to promote the expression of *Jag1* in smooth muscle cells ([@bib45]). During TE establishment, YAP and Notch have also been shown to interact through SBNO1, and act synergistically to regulate *Cdx2* ([@bib80]). In this context, our results show that both pathways are acting in parallel since there is no correlation among YAP and CBF1-VENUS expression levels in single blastomeres in morula stage embryos. In addition, loss of the NOTCH1 receptor or RBPJ does not affect YAP/TEAD4 localisation and vice versa, *Tead4* knockout does not alter CBF-VENUS expression in the blastocyst. Nevertheless, several components of the Hippo pathway are downregulated in *Rbpj^-/-^* morulae, so we cannot rule out the possibility of cross-transcriptional regulation between the pathways.

The role of Notch signalling in the specification of cell fates during development has been widely studied ([@bib35]). Notch promotes heterogeneities and reinforces differences between neighbouring cells, explaining the segregation of cell fates in multiple processes and in different species ([@bib2]). The heterogeneous activity of CBF-VENUS in the 4-cell stage coincides with the loss of cell equivalence and emergence of differences among blastomeres. Other factors have been shown to be differentially expressed among blastomeres of the 4 cell mouse embryo ([@bib4]; [@bib15]), suggesting that this is the moment when cells lose their homogeneous state to start desynchronizing and differentiating. Interestingly, *Prdm14*, one of these factors, and Notch show divergent patterns of expression during development. *Prdm14* is first expressed at the 2- and 4-cell stage, to be turned off and then re-expressed in the ICM of the blastocyst and later in the primordial germ cells ([@bib4]; [@bib88]). In contrast, the Notch pathway, as revealed by the CBF-Venus reporter, begins to be active at the 4-cell stage, it is active in most of the cells of the morula, and is later restricted to the TE of the blastocyst. After implantation, Notch activity is detected throughout the epiblast ([@bib56]). It has been suggested that *Prdm14* expression coincides with conditions where groups of cells show an undetermined state, while Notch is activated when cells transition towards their next developmental phase. Our results suggest that Notch would be regulating these transitions by downregulating *Prdm14* expression. In line with the upregulation of *Prdm14* in embryos that lack Notch activity, we observed in the RNA-seq data from *Rbpj*^-/-^ morulae a downregulation of Fgf receptors (*Fgfr1*, *2* and *3*) and DNA methyltransferases (*Dnmt3b*, *Dnmt1*), which are known to be repressed by PRDM14 ([@bib16]; [@bib89]). It is also interesting to note that in our mosaic ES cell experiments, Notch levels correlate with those of *Prdm14* and *Dppa3*, but not with other pluripotency markers such as *Nanog* or *Esrrb*. Therefore, Notch is not simply turning off the general pluripotency network to promote differentiation, but acting on a subset of early naïve pluripotency markers.

Interplay between Notch and chromatin remodellers has been reported in several situations ([@bib70]). Expression changes in chromatin modifiers precede the action of transcription factors that consolidate lineage choices during preimplantation development ([@bib4]). Therefore, these alterations suggest that *Rbpj^-/-^* embryos do not established correct epigenetic landscapes, do not switch off early markers such as *Prdm14* or *Dppa3* and are not able to properly trigger differentiation programs leading to a delay in the expression of lineage specifiers such as *Cdx2*. In this regard, it is interesting to note that *Rbpj* mutant morulae downregulate *Chaf1a*, which encodes the large subunit of the histone-chaperone CAF-1. Loss of CAF-1 promotes ES cells to transit to an earlier, totipotent 2-cell-like state ([@bib30]), and acts as a barrier for reprogramming ([@bib6]). Furthermore, knockout of *Chaf1a* leads to developmental arrest at the 16-cell stage and a loss of heterochromatin ([@bib28]). Thus, CAF-1 acts as a driver of differentiation in pluripotent cells. Interestingly, studies in *Drosophila* have shown that CAF-1 mediates downstream effect of the Notch pathway ([@bib93]). On the other hand, *Asf1a*, which encodes another histone chaperone, is among the few genes observed to be upregulated in *Rbpj^-/-^* embryos. Forced expression of *Asf1a* promotes reprogramming of human ES cells ([@bib14]), revealing a critical role in maintaining pluripotency. Furthermore, *Suv39h1*, a regulator of H3K9me3-heterochromatin that restrict cell plasticity and stemness ([@bib86]), is also downregulated in Notch loss-of-function morulae. In conclusion, we observed that during preimplantation development, Notch regulates critical epigenetic components that mediate transitions along the progressive restriction of potency that occurs in the early embryo.

In this study, we have also identified novel putative targets positively regulated by the Notch pathway, such as *Tle4* and *Tbx3* whose role in the exit from pluripotency has been described in ES cells ([@bib38]; [@bib66]; [@bib78]). Their increase in expression from 2 cell to morula supports their possible role in promoting early differentiation in vivo as well. TLE4 does not bind directly to DNA, but associates with other proteins to act as a transcriptional corepressor ([@bib34]). It will be of great interest to identify its transcriptional partners during preimplantation development and elucidate the mechanism by which it allows cell differentiation in this context. The role of TBX3 is more complex since, in addition to promoting differentiation, it has also been associated with pluripotency maintenance ([@bib22]; [@bib54]). Furthermore, in vivo TBX3 is detected in most of the cells of the morula but it is later restricted to the ICM ([@bib66]), following a complementary pattern to Notch. Thus, *Tbx3* regulation must involve Notch-dependant and Notch-independent inputs, what could explain why the mutation or deletion of the RBPJ motif present in the intronic *Tbx3* regulatory element did not disrupt enhancer activity or endogenous expression.

The role of Notch in ES cells had already been explored in the context of neural differentiation ([@bib43]). Blocking Notch signalling prevents ES cells from adopting a neural fate while its overexpression increases the frequency of neural specification. Our results suggest that Notch might have a more general role in promoting early differentiation, with a more specific function in neural specification at later stages ([@bib43]). In summary, our findings suggest that Notch acts by promoting the gradual loss of potency in the early embryo, which is subsequently reinforced by additional mechanisms, such as heterochromatin formation before the morula stage, or differential activation of the Hippo pathway at the morula-to-blastocyst transition. Therefore, in order to correctly specify a given lineage, such as the trophectoderm, Notch is simultaneously activating fate choice markers such as *Cdx2* and inducing a differentiation-prone state by lowering levels of naïve markers.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                        Source or reference                             Identifiers                                                        Additional information
  (species) or resource                                                                                                                                                                   
  --------------------------------- ---------------------------------- ----------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------
  Strain\                           CD1                                Charles Rivers                                                                                                     
  (*Mus musculus*)                                                                                                                                                                        

  Strain (*Mus musculus*)           C57Bl/6                            Charles Rivers                                                                                                     

  Strain (*Mus musculus*)           CBA                                Charles Rivers                                                                                                     

  Genetic reagent (*M. musculus*)   CBF1-VENUS                         [@bib56]                                        [MGI:5487911](http://www.informatics.jax.org/strain/MGI:5487911)   Dr. Anna-Katerina Hadjantonakis

  Genetic\                          Rbpj null                          [@bib57]                                        [MGI:1857411](http://www.informatics.jax.org/allele/MGI:1857411)   Dr. Jose Luis de la Pompa
  reagent (*M. musculus*)                                                                                                                                                                 

  Genetic reagent (*M. musculus*)   Notch1 null                        [@bib10]                                        [MGI:1857230](http://www.informatics.jax.org/allele/MGI:1857230)   Dr. Jose Luis de la Pompa

  Genetic reagent (*M. musculus*)   Tead4 null                         [@bib51]                                        [MGI:3770620](http://www.informatics.jax.org/allele/MGI:3770620)   Dr. Hiroshi Sasaki

  Genetic reagent (*M. musculus*)   iChr-Control-Mosaic                [@bib58]                                        [MGI:6108166](http://www.informatics.jax.org/allele/MGI:6108166)   Dr. Rui Benedito

  Genetic reagent (*M. musculus*)   iChr-Notch-Mosaic                  [@bib58]                                                                                                           Dr. Rui Benedito

  Genetic reagent (*M. musculus*)   Polr2a-CreERT2                     [@bib18]                                        [MGI:3772332](http://www.informatics.jax.org/allele/MGI:3772332)   Dr. Miguel Torres

  Cell line\                        iChr-Notch-Mosaic ESC              [@bib58]                                                                                                           Dr. Rui Benedito
  (*M. musculus*)                                                                                                                                                                         

  Antibody                          anti-CDX2\                         BioGenex                                        MU392-UC                                                           (1:200)
                                    (mouse monoclonal)                                                                                                                                    

  Antibody                          anti-CDX2\                         Abcam                                           ab76541                                                            (1:200)
                                    (rabbit\                                                                                                                                              
                                    monoclonal)                                                                                                                                           

  Antibody                          anti-YAP (mouse\                   Santa Cruz Biotechnology                        sc-101199                                                          (1:200)
                                    monoclonal)                                                                                                                                           

  Antibody                          anti-pERM (rabbit polyclonal)      Cell Signalling                                 3141                                                               (1:250)

  Antibody                          anti-E-Cadherin (rat monoclonal)   Sigma                                           U3254                                                              (1:250)

  Antibody                          anti-TEAD4 (mouse monoclonal)      Abcam                                           ab58310                                                            (1:100)

  Antibody                          anti-DsRed (rabbit polyclonal)     Living Colors, Clontech                         632496                                                             (1:400)

  Antibody                          anti-GFP (goat polyclonal)         Acris, Origene                                  R1091P                                                             (1:200)

  Antibody                          anti-HA (rat monoclonal)           Sigma                                           11867423001                                                        (1:200)

  Recombinant DNA reagent           Tle4-up_H2BmRFP                    This paper                                                                                                         modified pBluescript vector

  Recombinant DNA reagent           Tbx3-i7_H2BmRFP                    This paper                                                                                                         modified\
                                                                                                                                                                                          pBluescript vector

  Sequence-based reagent            qPCR primers                       This paper                                                                                                         See[Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Commercial assay or kit           PicoPure RNA Isolation Kit         ThermoFisher                                    KIT0204                                                            

  Chemical compound, drug           RO4929097                          Selleckchem                                     S1575                                                              

  Chemical compound, drug           Verteporfin                        Sigma                                           SML0534                                                            

  Software, algorithm               MINS                               [@bib42]                                                                                                           

  Software, algorithm               GraphPad Prism                     [www.graphpad.com](http://www.graphpad.com)     RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)       

  Software, algorithm               Fiji                               fiji.sc                                         RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)       

  Software,\                        R Project for\                     [www.r-project.org](http://www.r-project.org)   RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)       
  algorithm                         Statistical Computing                                                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animal experimentation {#s4-1}
----------------------

The following mouse lines were used in this work: *CBF1-VENUS* ([@bib56]), *Rbpj* null ([@bib57]), *Tead4* null ([@bib51]), *Notch1* null ([@bib10]), *iChr-Notch-Mosaic* ([@bib58]), *iChr-Control-Mosaic* ([@bib58]), *Polr2a^CreERT2^* ([@bib18]). All the lines were maintained in heterozygosis in an outbred background. Adults were genotyped by PCR of tail-tip DNA using primers and conditions previously described for each line. For preimplantation embryos, genotyping was performed directly on individually isolated embryos after recovery, culture or antibody staining.

Mice were housed and maintained in the animal facility at the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain) in accordance with national and European Legislation. Procedures were approved by the CNIC Animal Welfare Ethics Committee and by the Area of Animal Protection of the Regional Government of Madrid (ref. PROEX 196/14).

Embryo collection and culture {#s4-2}
-----------------------------

Females from the different mouse lines or outbred CD1 were superovulated as previously described ([@bib3]), except in the case of embryos to be used for RNA-seq. For embryo culture, zygotes were collected from oviducts, treated with hyaluronidase (Sigma) to remove cumulus cells and cultured until the desired stage at 37.5°C, 5% CO~2~, in M16 medium (Sigma) covered with mineral oil (NidOil, EMB). For experiments that did not require culture, embryos were collected at morula or blastocyst stage by flushing the oviduct or the uterus with M2 medium (Sigma) and fixed.

Immunofluorescence of preimplantation embryos {#s4-3}
---------------------------------------------

Immunofluorescence was performed as previously described ([@bib11]). The following antibodies and dilutions were used: monoclonal mouse anti-CDX2 (MU392-UC, BioGenex) 1:200, rabbit monoclonal anti-CDX2 (ab76541, Abcam) 1:200, mouse monoclonal anti-YAP (sc-101199, Santa Cruz Biotechnology) 1:200, rabbit polyclonal anti-pERM (3141, Cell Signalling) 1:250, rat monoclonal anti-E-Cadherin (U3254, Sigma) 1:250, mouse monoclonal anti-TEAD4 (ab58310, Abcam) 1:100, rabbit polyclonal anti-DsRed (632496 living colors Clontech) 1:400, goat polyclonal anti-GFP (R1091P, Acris, Origene) 1:200, rat monoclonal anti-HA (11867423001, Sigma) 1:200. Secondary Alexa Fluor conjugated antibodies (Life Technologies) were used at 1:1000. Nuclei were visualized by incubating embryos in DAPI at 1 μg/ml.

Imaging and quantification {#s4-4}
--------------------------

Images of antibody-stained embryos were acquired on glass-bottomed dishes (Ibidi or MatTek) with a Leica SP5, Leica SP8 or Zeiss LSM880 laser scanning confocal microscopes. The same parameters were used for imaging each experiment. Semi-automated 3D nuclear segmentation for quantification of fluorescence intensity was carried out using MINS, a MATLAB-based algorithm (<http://katlab-tools.org/>) ([@bib42]), and analysed as previously described ([@bib67]). To correct z-associated attenuation, intensity levels were fit to a linear model. Mitotic and pyknotic nuclei were excluded from the analysis. For defining cells as positive or negative for a given nuclear marker, we ordered cells by intensity levels and established a threshold for each experiment based on manual verification of the point where nuclear and cytoplasmic signals were equal. This process was repeated independently for each set of embryos processed and imaged in parallel, to overcome inter-experimental variability.

For live imaging, embryos were cultured in microdrops of KSOM on glass-bottomed dishes (MatTek) in an environmental chamber as described previously ([@bib85]). Images were acquired with a Zeiss LSM880 laser scanning confocal microscope system using a 40x objective. An optical section interval of 1.5 μm was acquired per z-stack, every 15 min.

Cell tracking of 3D-movies was carried out using a TrackMate plugin in Fiji ([@bib12]; [@bib69]; [@bib72]). The 3D reconstruction of the embryos and position of the cells was done using MatLab. The shape of the embryos was fitted into an ellipse and the coordinates in X, Y, Z for each blastomere were normalised to the centroid of the ellipse. The algorithm assigned an inner or outer position to each blastomere according to an established threshold, and they were manually verified. The intensity levels of VENUS fluorescent protein in each cell and time point were normalised according to the Z-position to correct the decay of signal intensity due to the distance with the objective ([@bib67]). The frequencies of the intensity levels for each embryo followed a Gaussian distribution. In order to compare different embryos, intensity levels were normalised so that the mean was 0 and the standard deviation was 1.

Pharmacological inhibitor treatments {#s4-5}
------------------------------------

Two-cell or morula stage embryos were cultured in drops of M16 medium (Sigma) covered with mineral oil (NidOil, EMB) at 37°C, 5% CO~2~, containing the corresponding pharmacological inhibitor or only DMSO as control until the corresponding stage. The following inhibitors and concentrations were used: 10 or 20 μM of the γ-secretase inhibitor RO4929097 (S1575, Selleckchem) ([@bib50]) and 10 μM of the TEAD/YAP inhibitor Verteporfin (SML0534, Sigma) ([@bib41]).

Quantitative-PCR {#s4-6}
----------------

RNA from pools of 25--30 embryos (for pharmacological inhibitor experiments) or from single embryos (for CRISPR/Cas9 editing) was isolated using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems) and reverse transcribed using the Quantitect Kit (Qiagen). RNA was isolated from ES cells with the RNeasy Mini Kit (Qiagen) and reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA was used for quantitative-PCR (qPCR) with Power SYBR Green (Applied Biosystems) in a 7900HT Fast Real-Time PCR System (Applied Biosystems). Expression of each gene was normalized to the expression of the housekeeping genes *Actin* (in mESC or pools of embryos) or *18S rRNA* (in single embryos). Primers used are detailed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

RNA-sequencing data analysis {#s4-7}
----------------------------

RNA-seq was performed on single morulae. cDNA synthesis was performed using SMART-Seq Ultra Low Input RNA Kit (Clontech). Library preparation and sequencing was performed by the CNIC Genomics Unit using the Illumina HiSeq 2500 sequencer. Gene expression analysis was performed by the CNIC Bioinformatics Unit. Reads were mapped against the mouse transcriptome (GRCm38 assembly, Ensembl release 76) and quantified using RSEM v1.2.20 ([@bib40]). Raw expression counts were then processed with an analysis pipeline that used Bioconductor packages EdgeR ([@bib65]) for normalisation (using TMM method) and differential expression testing. Expression data of *Rbpj* and *Neo* were used to genotype the samples. Three mutant and three control (two wildtype and one heterozygote) embryos were selected for analysis. Changes in gene expression were considered significant if associated to Benjamini and Hochberg adjusted p-value\<0.05.

RBPJ binding motifs were located according to the consensus motif from CIS-BP database (M6499_1.02 motif) using FIMO ([@bib17]). Association of RBPJ motifs to DEG was performed using BEDTOOLS ([@bib60]) using a 10 Kb window surrounding the transcriptional start site of genes. ATAC-seq data from 8-cell stage embryos ([@bib84]) was mapped to the GRCm38 assembly and integrated with the coordinates of RBPJ motifs previously detailed.

Sequencing data have been deposited at GEO under accession number GSE121979.

Transient transgenic assay {#s4-8}
--------------------------

For the generation of transient transgenics, F1 (C57Bl/6 x CBA) females were superovulated to obtain fertilized oocytes as described ([@bib3]). Each construct was microinjected into the pronucleus of fertilized oocytes at E0.5 at a concentration of 2 ng/μl. Microinjected oocytes were cultured in microdrops of M16 medium (Sigma) covered with mineral oil (NidOil, EMB) at 37°C, 5% CO~2~ until the morula stage.

Each fragment to be tested was amplified from mouse genomic DNA using NEBuilder HiFi DNA Assembly kit (New England Biolabs) and cloned into a modified pBluescript vector ([@bib91]) containing a H2BmRFP reporter gene under the control of the human beta-globin minimal promoter and including an SV40 polyadenylation signal. Primers for amplifying and cloning the 700 bp Tle4-up region are ctatagggcgaattggagctcTTCTTTAGAGGCACCAGTC and ggatccactagttctagagcggccgcATAAAGCCATTTTGCTTAACTG. Primers to amplify and clone the 600 bp Tbx3-i7 region are ctatagggcgaattggagctcCAAGCCAGCCTCAGTCCC and ggatccactagttctagagcggccgcCACACAAGCTTGCCAGCC. Lower case indicates sequence annealing to the plasmid and capital letters indicates sequence annealing to the genome. Constructs were linearized and plasmid sequences removed before microinjection. For H2BmRFP detection, embryos were fixed in 4% paraformaldehyde for 10 min at room temperature and immunostained. Any embryo showing at least one cell expressing the reporter was scored as positive. Due to mosaicism and variability in the amount of transgene present per cell, signal intensity of the reporter cannot be used as a reliable measure of enhancer activity in these assays. When using an empty vector containing only the minimal promoter and the reporter as a negative control, we routinely obtained H2BmRFP expression in approximately 10% of embryos ([@bib64]).

Mutagenesis {#s4-9}
-----------

Mutated version of Tle4-up (Tle4-up mut^RBPJ^) was generated by site-directed mutagenesis (Mutagenex Inc), changing the TGTGGGAAA binding motif to TGTccGAAA. Mutated version of Tbx3-i7 (Tbx3-i7 mut^RBPJ^) was generated using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) changing CGTGGGAAA to CGTccGAAA. Lower case indicates the altered residues. Changes that abolish RBPJ binding were based on previously described mutated versions of the binding site ([@bib77]).

CRISPR/Cas9 genome editing {#s4-10}
--------------------------

Two guide-RNAs at 60 ng/µl were incubated with tracRNA (Sigma) at 240 ng/µl for 5 min at 95°C. The hybridised gRNAs were then incubated with the Cas9 protein (PNA bio) at 30 ng/µl for 15 min at RT and microinjected into the pronuclei of (CBAxC57) F1 zygotes. sgRNAs were designed using the CRISPOR tool (<http://crispor.tefor.net/>) ([@bib20]). The following guide RNAs were used: *Tle4*, TTAGCCTGCACTTCGAGTTA and CCCAATTCAAGGCGTTCTGT; *Tbx3*, TAACCCTTTAGAGATAGGCT and TACCAGAGAGGTTTCCTACT. Embryos were recovered at E2.5 and lysed in 50 µl extraction buffer from the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems). Aliquots of 10 µl were used for DNA extraction for PCR genotyping. Mosaic embryos were those where we detected both the deleted and the wildtype allele. The remaining 40 µl were used for RNA extraction for RT-qPCR. To characterize the deletions generated, after PCR genotyping deleted bands of some embryos were gel purified, cloned and sequenced.

Cell culture {#s4-11}
------------

iChr-Notch-Mosaic ES cells were generated by Rui Benedito at CNIC and have been tested negative for *Mycoplasma* by the CNIC Cell Culture Facility. Cells were cultured in standard ESC media (DMEM, Gibco) supplemented with 15% foetal bovine serum (HyClone), 1% Glutamine, 1% NEAA (Hyclone), 0.1% ß-mercaptoethanol (Sigma) and LIF (produced in-house) or 2i (CHIR-99021, Selleckchem; and PD0325901, Axon) in dishes seeded with a feeder layer of mouse embryonic fibroblasts (MEFs). Cells were transfected with a *Cre* expressing plasmid to induce recombination using Lipofectamine 2000 (Invitrogen) for 24 hr. After recombination, cells were sorted using a Becton Dickinson FACS Aria Cell Sorter. To promote spontaneous differentiation, cells were cultured on gelatine-covered dishes for 48--72 hr after LIF or 2i + LIF removal in DMEM (Gibco) supplemented with 20% serum, 1% Glutamine and 0.1% ß-mercaptoethanol (Sigma).

Statistics {#s4-12}
----------

Statistical analyses were performed with GraphPad Prism seven or R studio. Data are presented as means ± s.d. or means ± s.e.m. as indicted in each case. Differences were considered statistically significant at p-value\<0.05. Tests used to calculate p-value are detailed in the figure legends. Student's t-test was used to compare two groups. ANOVA with Fisher or Bonferroni post-test was used to compare several groups. Fisher's exact test was used to compare distributions.
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Decision letter

Robertson

Elizabeth

Reviewing Editor

University of Oxford

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Transitions in cell potency during early mouse development are driven by Notch\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kevin Struhl as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All three reviewers were enthusiastic about the findings suggesting a role for Notch signalling in regulating *Cdx2* expression in the pre-implantation mouse embryo, and the identification of *Tle4* as a Notch-signalling target and agree that the work is, in principle, very suitable for publication in *eLife*. You will see that the reviewers require substantial additional experimental support for your conclusions.

Essential revisions:

In revising the manuscript we would ask you in particular to address the four main concerns raised during the review process, namely 1) to improve the data to substantiate your claim that Notch signalling regulates cell positioning 2) to increase the number of *Rbpj^-/-^* embryos subjected to single cell sequencing 3) strengthening of the data that shows that Notch and Hippo operate in parallel and 4) a more in-depth analysis of the differentiation potential of iChr-Notch mosaic ES cell.

The issues raised with regard to these points are clearly articulated in the reviewers' comments below.

*Reviewer \#1:*

During the preimplantation period of mammalian development, cell potency is gradually diminished as cells adopt distinct fates, including inner cell mass and trophectoderm. This interesting study from Menchero and colleagues examines the role of the Notch signaling pathway in regulating expression of *Cdx2* in mouse preimplantation embryos. CDX2 is widely acknowledged to be an important regulator of trophectoderm cell fate, and the role of Hippo signaling in regulating *Cdx2* is well established. By comparison, the role of Notch signaling in regulating CDX2 and cell fate is a relatively new topic of inquiry, as is the connection between Notch and Hippo signaling.

The authors employ a variety of clever and sophisticated new genetic tools to manipulate and measure Notch signaling in the embryo. From their analyses, the authors conclude that Notch signaling promotes expression of the trophectoderm gene *Cdx2* starting at the 4-cell stage. They conclude that Notch signaling is active before the stage that Hippo signaling is active in embryos. They further claim that Notch signaling dictates cell position, which is important because cell position is thought to dictate trophectoderm versus inner cell mass fate. They also identify new targets of Notch signaling by RNA-seq and evaluate the roles of these genes in ES cell differentiation.

All of these findings would be of broad interest to embryologists, stem cell biologists, and signaling pathway enthusiasts. However, the evidence to support the study\'s most exciting conclusions are still quite preliminary (see below). Therefore, while this study has the potential to provide exciting new insight to signaling in blastocyst formation, the story does not yet rest on a concrete foundation, and it\'s really hard to know if the authors\' model is accurate.

• Replication unknown. For the majority of figures, the sample size is not reported (neither for number of embryos examined nor for the number of embryo cells examined). Therefore, it is not possible to evaluate whether the reported phenotypes are highly penetrant or even representative.

• Ambiguous embryo staging. Throughout the manuscript, the authors refer to embryos at the morula stage. However, the morula stage encompasses several dynamic stages (8-cell to \<32-cell stage). Therefore, it is not possible to know that the comparisons are apples-to-apples across different litter, treatments, and culture conditions, without a more granular view (precise embryo cell number counts). For example, in Figure 1---figure supplement 4, are the *Tead4* null embryos the same cell number? Could this explain the increase in CDX2 expression (as opposed to overexpression of NICD)

• In several places, the data seem overinterpreted. For example:

\- Figure 2: the claim is made that Verteporfin and RO4929097 inhibit YAP/TEAD and Notch signaling, respectively. However, the authors do not provide an independent assessment of the efficacy of these particular treatments. Does each treatment window allow RO inhibit expression of the N signaling reporter CBF1? Does Verteporfin inhibit the nuclear localization of YAP (as shown by Wang et al., 2016)? While the authors provided some of these data in their previous manuscript (Rayon et al., 2014), the treatment windows differ between the two studies. Without knowledge of the degree of inhibition, it is not possible to rule out the possibility that a signaling pathway is active in a particular time or place.

\- Figure 4: the authors state that N signaling determines cell positioning. However, the authors have not confirmed whether the genetic manipulations (overexpression of NICD or dominant-negative MAML indeed affect N signaling in this setting as assumed. Another concern with this figure is whether an increase in ICM contribution is meaningful, when there were so few N loss of function cells surveyed to begin with (n = 6 cells). Increasing the sample size would be one way to address this. Finally, it is nice that wild type, unrecombined cells serve as an internal control in these experiments. However, I am slightly concerned that there is no control to examine whether the fluorescent proteins themselves or some other feature not related to Notch, could skew cellular contributions. This is a relatively minor concern. Finally, \"Different N levels determines cell position\" seems an overly strong conclusion, since many cells with altered N signaling do not change position.

-- For the RNA-seq analysis of *Rbpj* null embryos, only two null embryos were evaluated (Figure 5). This probably does not provide adequate biological replication and could explain why one of the proposed RBPJ targets (*Tbx3*) was a false positive.

• In some places, the data do not support the conclusions stated.

\- The conclusion that Notch, but not YAP/TEAD4 are essential for regulating expression of *Cdx2* prior to blastocyst formation is based on analysis of qPCR data shown in Figure 2A, where *Cdx2* levels are compared between treated and control embryos (left and right panels). However, if you compare the *Cdx2* expression levels in RO-treated and Verteporfin-treated embryos, their levels are similar. By contrast, it is the variation within the control embryos that makes it seem like the effect of RO is statistically significant while the effect of the Verteporfin is not. Finally, do Rbpj null embryos phenocopy RO treatment at the early/morula stage?

\- Subsection "Absence of crosstalk between the Notch and Hippo signalling pathways in the early mouse embryo", last paragraph: if the maternally provided Cre recombines in oocytes, then no mosaicism should be observed in embryo cell recombination. Do the authors mean that the maternally provided Cre recombines during the embryonic stages? Probably this is just a semantic issue.

*Reviewer \#2:*

Having previously shown that Notch signalling regulates the expression of CDX2 in conjunction with YAP/TEAD complexes in TE cells, the authors investigate the role of the pathway during early preimplantation development. Using a variety of approaches (pharmacological, genetic), the authors claim that Notch plays an unexpected role in regulating genes that act as repressors of early naïve pluripotency prior to compaction, thereby initiating differentiation events that drive early specification of the trophectoderm.

The manuscript is clearly written and presents potentially interesting findings. However, in some cases, it was let down by either its experimental design, a lack of extensive controls or an inappropriate number of independent biological replicates. Please find below a list of major points that I think need to be addressed before the manuscript is ready for publication

1\) The importance of Notch signalling during early preimplantation development

If Notch signalling is crucial prior to compaction to initiate TE differentiation, it is not clear why *Rbpj^-/-^* embryos develop into apparently morphologically normal blastocysts (Figure 1---figure supplement 2) and have also completely recovered a normal CDX2 expression pattern after the 16 cell-stage (Figure 2E-F).

2\) Lack of quantification of CDX2 nuclear levels in mutant embryos

The authors present results obtained with *Rbpj^-/-^* embryos and the impact on CDX2 expression in a separate figure to Figure 1 which makes comparisons between the various genotypes difficult. CDX2 nuclear levels seem lower in *Rbpj^-/-^; Tead4^+/-^* and *Rbpj^+/-^; Tead4^-/-^* embryos (Figure 1A), whereas in *Rbpj^-/-^* embryos cells are either described as positive or negative for CDX2 (Figure 2C). This discrepancy is unexplained in the manuscript but proper quantification of nuclear CDX2 would go some way in properly describing the results and allow comparisons between embryos of different genotypes.

3\) Absence of description of *Tead4^-/-^* embryos

It seems that the data for *Tead4^-/-^* embryos is not presented in Figure 1A and elsewhere in the manuscript. Since a previous report suggests that TEAD4 accounts for most of CDX2 expression in the nucleus at E2.5 (Yagi et al., 2007), it needs to be addressed whether it is truly the case to find what is the exact contribution of both Notch and YAP/TEAD4. In particular at the 8-cell stage, since the authors claim that \"there is an earlier requirement for Notch than for Hippo in the regulation of *Cdx2*, and that both pathways exert non-redundant roles\".

4\) Weak effect of N1ICD in *Tead4^-/-^* embryos on CDX2 expression

In Figure 1---figure supplement 4, expressing N1ICD in *Tead4^-/-^* embryos seems to have a marginal effect at best (albeit significant) as nuclear CDX2 intensity levels go up from around 2.25 to 2.50. It seems that this was quantified at the E3.5. Considering the authors\' conclusions regarding the role of Notch signalling prior to the morula stage, it seems that it would be more relevant to investigate the effect of N1ICD in *Tead4^-/-^* embryos at earlier stages and it may be that nuclear CDX2 expression is rescued more impressively at these stages. Additionally, to further asses the relative importance of Notch and *Tead4* at early stages, the reverse experiment would be to try and rescue nuclear CDX2 expression in *Rbpj^-/-^* embryos using a constitutively active form of TEAD4 for instance.

5\) Lack of clarity in the GOF and LOF regarding recombination events

In the GOF and LOF experiments, the authors resort to immunostaining to identify the different cell recombination events. However, the GOF cells were triple positive because of antibody cross-reactivity. In addition, the images presented are unclear and, the examples given, fail to alleviate concerns about the validity of the approach and why it was used. If fixation reduced the fluorescence signal, could the embryos have been imaged live prior to that? Alternatively, have the authors attempted to validate their method by other means (by genotyping after immunostaining of individual dissociated blastomeres for example)? The fact that the less likely recombination event was observed the most often using this method adds to the concern that it may not accurately identify the right type of cell.

6\) Number of independent biological replicates in RNA-seq experiments

Only 2 *Rbpj^-/-^* morulae were used in RNA-seq experiments. It seems unreasonable to justify this by the decision of wanting to strictly compare litter mates.

7\) Quantification of transient transgenic experiment

Figure 5E-F -- It is not clear why the authors quantified positive and negative embryos. Unless I misunderstood the experiment, it seems that embryos injected with the mutated transcriptional enhancer should either drive H2B-mRFP weakly or not at all in comparison to the wild type construct. As a result, it seems that signal intensity should have been quantified instead.

8\) CRISPR experiment

Figure 5G -- Not enough information is provided to understand what mutations were obtained in the CRISPR experiment. Was a repair construct lacking the enhancer sequence introduced to generate a knockin in the endogenous locus? If not, were the different mutated embryos harbouring the same mutations?

*Reviewer \#3:*

The current manuscript by Menchero and colleagues describes an analysis of the role of Notch signalling during early pre-implantation development. The authors had previously shown that Notch and Yap/Tead signalling act together to specify trophectoderm (TE) identity. Here using a series of elegant single cell expression analyses combined with genetic and inhibitor experiments they demonstrate that these are parallel pathways, with Notch signalling acting earlier than Hippo signalling to affect *Cdx2* expression and control TE fate. Importantly, by studying null mutants for the Notch effector *Rbpj* as well as using mosaic Notch gain and loss of function mutations, they also identify that Notch signalling appears to regulate not only TE fate, but have a more general role in promoting differentiation.

Together, these are very interesting findings that provide important new insight into pre-implantation development. The role of FGF and Hippo signalling have been extensively analysed, therefore insight into the roles of other pathways is welcome. The analysis of the relative roles of Notch and Hippo on the regulation of TE fate is conclusive. In contrast to this, the manuscript would benefit from some clarification regarding the role of Notch signalling in the exit of naive pluripotency. Specifically, it would be important to understand if *Rbpj*/Notch signalling is required for this process or if the regulation of *Prdm14* and *Dppa3* is reflecting other roles of Notch signalling. Therefore, it would be interesting to have a broader picture of the role of Notch in exit of pluripotency and if *Tle4* is an important target during this process. Using naïve pluripotent ES cells (2i+Lif) and their differentiation will most likely be the most straightforward way to address this question.

10.7554/eLife.42930.040

Author response

> Essential revisions:
>
> In revising the manuscript we would ask you in particular to address the four main concerns raised during the review process, namely:
>
> 1\) To improve the data to substantiate your claim that Notch signalling regulates cell positioning.

We have further substantiated our claim that Notch signalling regulates cell position in the preimplantation embryo and the validity of the Notch mosaic mouse model by:

\- increasing the number of cells examined at the morula stage in the iChr-Notch-Mosaic model.

\- using non-recombined blastomeres in morula and blastocyst mosaic as a second internal control.

\- checking the specificity of the antibody panel used to distinguish different recombination events in embryos by testing them in fluorescent-based sortied ES cells pf the same genotype as the iChr-Notch-Mosaic mice.

\- including a new control using a mouse line carrying the same construct as the iChrNotch-Mosaic, but that does only carry the fluorescent proteins with no fusions to DNMaml1 or NICD (iChr-Control-Mosaic).

These results are now shown in revised Figure 4, Figure 4---figure supplement 1, and Figure 4---figure supplement 3.

> 2\) To increase the number of Rbpj^-/-^ embryos subjected to single cell sequencing.

We have included a further *Rbpj*^-/-^ embryo in the RNA-seq and re-done the analysis, confirming our previous results. These results are now shown in revised Figure 5, Figure 5---figure supplement 1, Figure 5---source data 1, and Figure 5---source data 2.

> 3\) Strengthening of the data that shows that Notch and Hippo operate in parallel.

We have considerably strengthened the data that shows that Notch and Hippo act in parallel by:

\- separating the data of the correlation analysis of CDX2, Yap and VENUS for morulas in two different windows based on cell number (8-16 and 17-32 cells).

\- increasing the number of Verteporfin treated embryos analysed by RT-qPCR in different time windows.

\- including new controls that show that drug treatments work as expected in these time windows by decreasing fluorescence from the CBF:VENUS reporter or downregulating known YAP-TEAD4 targets in preimplantation embryos.

These results are now shown in revised Figure 1, Figure 1---figure supplement 2, Figure 2, and Figure 2---figure supplement 1.

> 4\) A more in-depth analysis of the differentiation potential of iChr-Notch mosaic ES cell.

We have carried out novel differentiation experiments of ES cells with different Notch levels that were grown and maintained in 2i+LIF conditions, in order to examine the their potential starting from the naïve state. These results are now shown in revised Figure 6---figure supplement 4.

> The issues raised with regard to these points are clearly articulated in the reviewers' comments below.

See response to each of the issues raised by the reviewers below, along with the description of the corresponding changes in the main text and in the figures.

> Reviewer \#1:
>
> \[...\] All of these findings would be of broad interest to embryologists, stem cell biologists, and signaling pathway enthusiasts. However, the evidence to support the study\'s most exciting conclusions are still quite preliminary (see below). Therefore, while this study has the potential to provide exciting new insight to signaling in blastocyst formation, the story does not yet rest on a concrete foundation, and it\'s really hard to know if the authors\' model is accurate.
>
> • Replication unknown. For the majority of figures, the sample size is not reported (neither for number of embryos examined nor for the number of embryo cells examined). Therefore, it is not possible to evaluate whether the reported phenotypes are highly penetrant or even representative.

We are sorry for not including this basic information and thanks the reviewer for pointing it out. We have carefully revised all of the data presented in the manuscript and included sample size where needed. For example, in the case of CDX2 staining in the different allelic combinations of the *Rbpj* and *Tead4* mutants, we have included the number of embryos analysed on top of the corresponding panels (Figure 1A and Figure 1---figure supplement 1A). In other cases (Figure 1---figure supplement 3, Figure 1---figure supplement 4, Figure 2---figure supplement 1) we have included this information in the figure legends. In all other cases, samples sizes (number of embryos and/or cells) are indicated in the figure legends.

> • Ambiguous embryo staging. Throughout the manuscript, the authors refer to embryos at the morula stage. However, the morula stage encompasses several dynamic stages (8-cell to \<32-cell stage). Therefore, it is not possible to know that the comparisons are apples-to-apples across different litter, treatments, and culture conditions, without a more granular view (precise embryo cell number counts). For example, in Figure 1---figure supplement 4, are the Tead4 null embryos the same cell number? Could this explain the increase in CDX2 expression (as opposed to overexpression of NICD)

We agree with the reviewer that cell number counts is a more accurate description of embryos stages in these time windows, and where possible we have separated the data from embryos in early (8-16 cells) and late (17-32) stages. We have done so for the correlations analysis of levels of CDX2, YAP and VENUS shown in Figure 1C and Figure 1---figure supplement 2, allowing us to observe nicely the gradual increase in correlation along development of CDX2 with VENUS (as a readout of Notch activity) and YAP, while correlation of Venus with YAP remains low until the blastocyst. We also show this distinction when we quantify nuclear levels of CDX2 in *Rbpj* and *Notch1* mutant embryos (Figure 2C-H and Figure 2---figure supplement 2A-F). We have also changed the image of the double heterozygous *Rbpj^+/-^;Tead4^+/-^* shown in Figure 1A so it is at the same 8-cell stage as other embryos shown in this panel (see response to reviewer \#2 below).

In the case of the pharmacological treatments (Figure 2A, B and Figure 5C), we could not accurately count cell numbers per embryo as these where live and directly placed in lysis buffer for RNA extraction. Manipulation such as fixing and staining nuclei would have compromised the quality of the RNA, thus not allowing to perform RT-qPCR on this limited amount of material.

As for the experiment of the rescue of the *Tead4* mutant phenotype by overexpression of N1ICD (shown in Figure 1---figure supplement 4 of the original version of the manuscript), we followed the reviewer's advice and carefully counted the number of cells of the embryos analysed. While on average embryos had 40-65 cells, one of the *Tead4^/-^* embryos was considerably earlier with only 25 cells. We therefore excluded this embryo from the analysis and included two new *Tead4^-/-^* embryos with a cell number within the range of the others previously analysed. When we repeated the comparison of nuclear CDX2 intensity levels between *Tead4^-/-^* and *N1ICD-GFP;Tead4^-/-^* embryos, we found no significant differences ([Author response image 1](#respfig1){ref-type="fig"}). In light of this result, and taking into account that we had previously argued that N1ICD only marginally rescues CDX2 expression levels in *Tead4^-/-^* but not its developmental phenotype, we have decided to remove this information from the present version of the manuscript (see also response to point 4 from reviewer \#2 below).

![Quantification of CDX2 intensity levels in *Tead4^-/-^* (n=153 blastomeres from 3 embryos) and *N1ICD-GFP;Tead4^-/-^* (n=224 blastomeres from 5 embryos) embryos.\
No significant differences in CDX2 levels was found between the two genotypes.](elife-42930-resp-fig1){#respfig1}

> • In several places, the data seem overinterpreted. For example:
>
> \- Figure 2: the claim is made that Verteporfin and RO4929097 inhibit YAP/TEAD and Notch signaling, respectively. However, the authors do not provide an independent assessment of the efficacy of these particular treatments. Does each treatment window allow RO inhibit expression of the N signaling reporter CBF1? Does Verteporfin inhibit the nuclear localization of YAP (as shown by Wang et al., 2016)? While the authors provided some of these data in their previous manuscript (Rayon et al., 2014), the treatment windows differ between the two studies. Without knowledge of the degree of inhibition, it is not possible to rule out the possibility that a signaling pathway is active in a particular time or place.

We agree with the reviewer that we do not formally show that drug treatments in the time windows used result in inhibition of the signalling pathways analysed. We have carried out new experiments to address this issue, treating embryos from the CBF1-VENUS line with the Notch pathway inhibitor RO4929097 from 2-cell to morula and from morula to blastocysts. In both cases, we observe a robust downregulation of VENUS expression, proving that we are effectively inhibition Notch signalling as expected. These results are shown in the new Figure 2---figure supplement 1, and nicely complement our previous findings (Rayon et al., 2014).

As for the effect of Verteporfin on Hippo signalling, it has been described that this drug acts by disrupting the association of the YAP/TEAD complex (Liu-Chittenden et al., 2012). It is true, as the reviewer points out, that the report by Wang et al., 2016 suggests that treatment with Verteporfin causes YAP translocation to the cytoplasm. We therefore examined in detail subcellular localization of YAP in Verteporfin and DMSO (control) treated embryos, but we did not observe changes in nuclear or cytoplasmic localization ([Author response image 2](#respfig2){ref-type="fig"}).

![Nuclear localization of YAP is not altered by Verteporfin treatment of preimplantation mouse embryos.\
*Left*, representative images of DMSO (n=3) and Verteporfin (10 µm; n=4) treated embryos stained for YAP; nuclei, stained with DAPI, are shown below. *Right*, quantification of nuclear YAP levels in DMSO and Verteporfin treated embryos. We observe no difference between treatments.](elife-42930-resp-fig2){#respfig2}

Nevertheless, we believe this does not mean that the drug is not acting as expected. The above-mentioned paper was carried out in tissue cultured cells, and from the images provided it is difficult to quantitatively assess the extent of nuclear-cytoplasmic shuffling of YAP. An independent way to support our claim that Verteporfin is interfering with YAP/TEAD4 in the time windows used, is to check the expression of known YAP/TEAD4 targets such as *Cdx2* (Yagi et al., 2007; Nishioka et al., 2008; Frum et al., 2018) or *Gata3* (Ralston et al., 2010). Sure enough, we observe a reduction in *Cdx2* expression in Verteporfin treated embryos from morula to blastocyst window (Figure 2B), and of *Gata3* (that is downstream of *Tead4* independently from *Cdx2*; Ralston et al., 2010) in embryos treated from 2-cell to morula (Figure 2A; and see below).

As for the degree of inhibition we obtain, we do not suggest that we are completely blocking the pathways. Pharmacological treatments at these stages are tricky, as high doses results in embryo lethality (usually due to high concentrations of the carrier, in this case DMSO), so at best we obtain a partial reduction. Nevertheless, these experiments also offer unique opportunities to treat the embryos in very precise time windows, what is not possible using genetic approaches.

> \- Figure 4: the authors state that N signaling determines cell positioning. However, the authors have not confirmed whether the genetic manipulations (overexpression of NICD or dominant-negative MAML indeed affect N signaling in this setting as assumed.

The reviewer points to a relevant issue, although difficult to assess in this experimental setting. An apparently obvious possibility, in view of the tools we have used in our work, would be to use the CBF1:VENUS reporter as a readout of Notch signalling with single cell resolution. However, apart from the difficulties involved in the breeding of three different alleles simultaneously (in terms of space in our animal facility and time), we would not be able to distinguish green fluorescence from the VENUS reporter or from the EGFP fusion to dominant negative MAML1.

The other possibility is to examine the expression of known Notch targets in other contexts, such as *Hes1* or *Hey* genes. However, data from our RNA-seq and that of others show that the levels of expression of these genes in mouse preimplantation development is zero or extremely low. Therefore, we decided to measure nuclear levels of CDX2 as a readout of Notch signalling, as this is the only bona-fide target of Notch identified and validated so far in mouse preimplantation stages. We find a perfect correlation between CDX2 and Notch activity determined by the loss- and gain-of-function systems used. We have included these new results in the revised version of the manuscript and show them in Figure 4---figure supplement 1B.

> Another concern with this figure is whether an increase in ICM contribution is meaningful, when there were so few N loss of function cells surveyed to begin with (n = 6 cells). Increasing the sample size would be one way to address this.

We agree with the reviewer this number was somewhat low, so we have setup and analysed more embryos from this cross in order to increase the sample size. We have now analysed 10 morula and 11 blastocysts. We used embryos containing cells derived from all three possible recombination events plus unrecombined cells, and also embryos that at least had recombined cells for both the Notch gain- and loss-of-function events (see response to reviewer \#2 below). We have now analysed 29 Notch loss-of-function cells in the morula instead of 6 as before. Alongside, we have also increased the sample size for all other events (unrecombined -- see below, wild-type recombined -- red, loss-of-function -- green, gain-of-function -- cyan) at both morula (69, 33, 29 and 83 cells respectively) and blastocyst (190, 87, 50 and 173 cells respectively) stages. Details are provided in the revised legend for Figure 4. In the new analysis, we still observe differential contribution of cells to inner or out positions dependant on Notch activity, although in a more gradual manner. For example, Notch loss-of-function cells are more frequently located in inner positions in the blastocyst (Figure 4E) and also in the morula (Figure 4D; although in this case just below the threshold of statistical significance, p=0.05).

> Finally, it is nice that wild type, unrecombined cells serve as an internal control in these experiments.

We thank the reviewer for this nice and very useful suggestion to use unrecombined cells as a second internal control in addition to the Cherry cells. We have counted these cell in both morula and blastocyst stages finding that their distribution in inner or outer positions is identical to recombined Cherry wild type cells (Figure 4D, E). As noted above, in this re-analysis we have included not only embryos in which we observe all three possible recombination events but also those in which we observed at least recombination leading to Notch loss- and gain-of-function cells (see also response to reviewer \#2 below). We have updated Figure 4C-E; Figure 4---figure supplement 2A, B; and Figure 4---figure supplement 3B, C (see below) with this data.

> However, I am slightly concerned that there is no control to examine whether the fluorescent proteins themselves or some other feature not related to Notch, could skew cellular contributions. This is a relatively minor concern.

The reviewer is right in noting that skews in distribution of cells harbouring different recombination events could be due to factors other than different activation state of the Notch pathway. in order to address this valid and important concern, we have carried out a new set of experiments in which we use a control mice line that carries the same construct as the Notch mosaic, but including only the fluorescent reporters not fused to dominant-negative MAML1 or constitutively active NICD (iChr-Control-Mosaic; PontesQuero et al., 2017), crossed with the *Polr2a^CreERT2^* driver as before (Figure 4---figure supplement 3A). When we examined the contribution of the different recombination events, we find that the majority correspond to Cherry+ cells (Figure 4---figure supplement 3B), the first and most probable event, in contrast to what we observed with the iChrNotch-Mosaic where Cerulean+ Notch gain-of-function cells were more abundant (Figure 4C). This control also shows that the type of recombination event that has taken place does not influence the in-out distribution of cells in the blastocyst (Figure 4---figure supplement 3C). Overall, this new set of control experiments confirms and further supports our previous claim that forced activation of the Notch pathway offer a competitive advantage to Cerulean+ cells that therefore are present in a higher than expected proportion in the resulting embryos.

> Finally, \"Different N levels determines cell position\" seems an overly strong conclusion, since many cells with altered N signaling do not change position.

We do agree with the reviewer that the title of this section was an over-interpretation. We have now changed it to \"Different N levels *influences* cell position\". We have also changed a sentence in the last section of the Introduction from "differences in Notch levels *determines* cell fate acquisition in the blastocyst" to "differences in Notch levels *contribute to* cell fate acquisition in the blastocyst" along the same line.

> \- For the RNA-seq analysis of Rbpj null embryos, only two null embryos were evaluated (Figure 5). This probably does not provide adequate biological replication and could explain why one of the proposed RBPJ targets (Tbx3) was a false positive.

We certainly have to agree with the reviewer that n=2 is a low number for analysis of *Rbpj*^-/-^ embryos. In our original analysis this was due to the technical hurdles involved in obtaining adequate material, as embryos where processed in batch and genotypes were only inferred later from sequence data. On the other hand, we have used this approach as an initial discovery tool to identify other putative Notch pathway targets, such as *Tle4*, that we then have confirmed by independent means. Nevertheless, we have carried out new RNA-seq experiments and been able to obtain data from another *Rbpj* null embryo. We have included this data and repeated the analysis, confirming and replicating our previous results and observations. We have updated Figure 5, Figure 5---figure supplement 1 and Figure 5---source data 1 and 2 correspondingly. We have also updated the GEO database entry with the newly generated data.

Regarding *Tbx3*, we still identify it as a differentially expressed gene containing a putative RBPJ site in an open chromatin region in its vicinity. We therefore do not think it is a false positive, as its expression is significantly reduced in RO treated embryos (Figure 5C). The fact that deletion of the putative RBPJ site does not affect enhancer activity in transient transgenic assays, and that the deletion of the corresponding genomic region does not reduce endogenous *Tbx3* expression suggests that this is not the only transcriptional input required. Further unidentified sites could be acting together with this unique RBPJ site, as is the case for the TEE enhancer we previously characterized for *Cdx2* (Rayon et al., 2014). A more detailed analysis of the regulation of *Tbx3* in the preimplantation embryo is of clear interest and will sure merit further work, but we believe it is out of the scope of the present manuscript.

> • In some places, the data do not support the conclusions stated.
>
> \- The conclusion that Notch, but not YAP/TEAD4 are essential for regulating expression of Cdx2 prior to blastocyst formation is based on analysis of qPCR data shown in Figure 2A, where Cdx2 levels are compared between treated and control embryos (left and right panels). However, if you compare the Cdx2 expression levels in RO-treated and Verteporfin-treated embryos, their levels are similar. By contrast, it is the variation within the control embryos that makes it seem like the effect of RO is statistically significant while the effect of the Verteporfin is not.

We have followed the reviewer's advice and increased the sample size for Verteporfin treated embryos in the 2-cell to morula time window. In this way, we have reduce the variability in DMSO treated embryos and still find no significant differences in *Cdx2* expression (Figure 2A), thus confirming our previous interpretation. Interestingly, what we do observe now is a significant downregulation of *Gata3* upon Verteporfin treatment in this early time window. As discussed above, *Gata3* has been established as a TEAD4 target independent of *Cdx2* (Ralston et al., 2010), so this might be reflecting this early input of Hippo signalling on *Gata3*. As for the differential early and late effects of Notch inhibition on *Cdx2* expression, we have confirmed the RTqPCR results independently by adding the quantification of nuclear CDX2 expression levels in early morula (8-16 cells) from *Rbpj* (Figure 2D, G) and *Notch1* (Figure 2---figure supplement 2B, E) null embryos (see also response to point 2 from reviewer \#2 below).

> Finally, do Rbpj null embryos phenocopy RO treatment at the early/morula stage?

Yes, as mentioned above we have now included detailed quantification of the nuclear levels of CDX2 in *Rbpj* and *Notch1* null embryos (Figure 2D, G; Figure 2---figure supplement 2B, E), showing a reduction of expression in early 8-16 cell morulas but not in later embryos. This data complements our previous estimate of the number of CDX2 positive cells in these embryos (now shown in Figure 2E, H; Figure 2---figure supplement 2C, F), providing a more fine-grained analysis.

> \- Subsection "Absence of crosstalk between the Notch and Hippo signalling pathways in the early mouse embryo", last paragraph: if the maternally provided Cre recombines in oocytes, then no mosaicism should be observed in embryo cell recombination. Do the authors mean that the maternally provided Cre recombines during the embryonic stages? Probably this is just a semantic issue.

The reviewer is right that if the maternal *Sox2-*CRE recombines in the oocyte, we should not expect mosaicism. However, as we noted in our previous work (Rayon et al., 2014), this Cre driver does result in mosaic recombination. Therefore, even if CRE is expressed in the oocyte as previously described (Hayashi et al., 2003, Genesis 37 51-3), it must be acting at later stages. Nevertheless, we have now removed this data from the revised version of the manuscript (see above).

> Reviewer \#2:
>
> \[...\] The manuscript is clearly written and presents potentially interesting findings. However, in some cases, it was let down by either its experimental design, a lack of extensive controls or an inappropriate number of independent biological replicates. Please find below a list of major points that I think need to be addressed before the manuscript is ready for publication

We thank the reviewer for the comments, which we have addressed in this revised version. Among other new experimental data, we have added controls as requested and also increased the number of biological replicates in key experiments.

> 1\) The importance of Notch signalling during early preimplantation development
>
> If Notch signalling is crucial prior to compaction to initiate TE differentiation, it is not clear why Rbpj^-/-^ embryos develop into apparently morphologically normal blastocysts (Figure 1---figure supplement 2) and have also completely recovered a normal CDX2 expression pattern after the 16 cell-stage (Figure 2E-F).

As we discuss extensively in this manuscript, as well as in our previous work (Rayon et al., 2014), we contend that the input of Notch is necessary in these early stages for the proper expression of TE markers such as *Cdx2* and to regulate cell position in the embryo. At no point do we conclude that Notch signalling, or *Rbpj*, is absolutely necessary to specify the TE, but that in acts in concert and along time with other signalling pathways such as Hippo in this process. The lack of an overt morphological phenotype affecting the TE indicates that this pathway is required but that it can be compensated by others triggered independently by cell polarisation. This fits with the hypothesis that the early mammalian embryo acts as a self-organizing system (Wennekamp et al., 2013), integrating genetic, morphological and physical forces to achieve its final form at the blastocyst stage. However subtle, the fact that double *Rbpj^-/-^;Tead4^-/-^*embryos fail to reach the blastocyst stage (Rayon et al., 2014) further supports a role for Notch, together with Hippo, in these early stages.

> 2\) Lack of quantification of CDX2 nuclear levels in mutant embryos
>
> The authors present results obtained with Rbpj^-/-^ embryos and the impact on CDX2 expression in a separate figure to Figure 1 which makes comparisons between the various genotypes difficult. CDX2 nuclear levels seem lower in Rbpj^-/-^; Tead4^+/-^ and Rbpj^+/-^; Tead4^-/-^ embryos (Figure 1A), whereas in Rbpj^-/-^ embryos cells are either described as positive or negative for CDX2 (Figure 2C). This discrepancy is unexplained in the manuscript but proper quantification of nuclear CDX2 would go some way in properly describing the results and allow comparisons between embryos of different genotypes.

We do agree with the reviewer that data at some points is distributed among multiple figures and panels, what can make direct comparisons not easy. We have tried different ways to correct this, but after multiple attempts we still believe that the way the data is presented is the best to follow the story. Regarding quantification of nuclear expression levels shown in Figure 1 for different genotypes, and as discussed the response to reviewer \#1 above, we were not able to quantify nuclear expression levels for CDX2 in this set of experiments due to inconsistencies in microscopy settings across different days and litters (see above). However, in an independent set of experiments where we examined nuclear CDX2 expression in morula stage *Rbpj*^-/-^ and *Notch1*^-/-^ embryos, we could carry out correct quantification and compare between embryos. This data is now shown in revised Figure 2D, G and Figure 2---figure supplement 2B, E.

> 3\) Absence of description of Tead4^-/-^ embryos
>
> It seems that the data for Tead4^-/-^ embryos is not presented in Figure 1A and elsewhere in the manuscript. Since a previous report suggests that TEAD4 accounts for most of CDX2 expression in the nucleus at E2.5 (Yagi et al., 2007), it needs to be addressed whether it is truly the case to find what is the exact contribution of both Notch and YAP/TEAD4. In particular at the 8-cell stage, since the authors claim that \"there is an earlier requirement for Notch than for Hippo in the regulation of Cdx2, and that both pathways exert non-redundant roles\".

We originally did not include this information due to the high number of different genotypes obtained from the cross for the double KO embryos (9 in total), that would have resulted in a too complex figure. However, we did show CDX2 expression in a 8cell stage *Rbpj^+/-^;Tead4^-/-^* embryo that we thought could be representative of the effect of lack of *Tead4* on CDX2 expression. Nevertheless, we have now completed this description by including the immunostaining for CDX2 in all genotypes in Figure 1---figure supplement 1B. Unfortunately, and as described above and in the response to reviewer \#1, we could not quantify accurately expression in this experiment, so we can only reach conclusions based on qualitative assessment of antibody stainings. In any case, we do feel sure enough to state that CDX2 is expressed in *Tead4*^-/-^ 8-cell embryos, although at lower levels than what can be observed in wildtypes, and not completely absent as we see in double KO embryos. This is in line with the cited work of Yagi et al. (Yagi et al., 2007) and that of other authors (Nishioka et al., 2008; Frum et al., 2018), that we have included in the revised text of the manuscript.

> 4\) Weak effect of N1ICD in Tead4^-/-^ embryos on CDX2 expression
>
> In Figure 1---figure supplement 4, expressing N1ICD in Tead4^-/-^ embryos seems to have a marginal effect at best (albeit significant) as nuclear CDX2 intensity levels go up from around 2.25 to 2.50. It seems that this was quantified at the E3.5. Considering the authors\' conclusions regarding the role of Notch signalling prior to the morula stage, it seems that it would be more relevant to investigate the effect of N1ICD in Tead4^-/-^ embryos at earlier stages and it may be that nuclear CDX2 expression is rescued more impressively at these stages. Additionally, to further asses the relative importance of Notch and Tead4 at early stages, the reverse experiment would be to try and rescue nuclear CDX2 expression in Rbpj^-/-^ embryos using a constitutively active form of TEAD4 for instance.

The reviewer rightly points out that there is only a weak effect of N1ICD in rescuing CDX2 expression in *Tead4*^-/-^ embryos. As a matter of fact, and following the advice of reviewer \#1, we carefully examined the cell number of the embryos analysed in this experiments. After removing a too early *Tead4*^-/-^ embryo, and despite including two other embryos with a comparable cell number (40-65), the reanalysis showed no significant difference in CDX2 expression (see above response to reviewer \#1 and [Author response image 1](#respfig1){ref-type="fig"}). The suggestion made by the reviewer that changes at the morula stage could be more prominent is certainly of interest. Unfortunately, the few mice from this colony we had available did not produce further litters. This is a complex breeding, which involves three different alleles (*Tead4-, Rosa26-stop-N1ICD-ires-eGFP*, and *Sox2Cre*) that we would need to generate from scratch. The time, space in the mouse facility, and effort this would mean made this experiment not feasible in a reasonable time frame in order to revise the manuscript. Therefore, and in light of the results described above and in the response to reviewer \#1, we have decided to remove this experiment from the revised version of the manuscript, We believe this does not affect significantly our work or change the conclusions reached.

As for the reviewer's suggestion to perform the reverse experiment, that is to rescue the expression of CDX2 in *Rbpj*^-/-^ embryos by forced expression of an active form of TEAD4, this would certainly be of great interest. However, this is an extremely complex experiment from a logistics point of view. We would need to generate and maintain a colony of *Rbpj*^+/-^ mice big enough to generate KO embryos in sufficient number. Due to the lethality of homozygotes, this would require separate heterozygous male (to use as studs) and female (to use for superovulation and the production of embryos) colonies. On top of that, embryos resulting from the het cross would need to be individually microinjected with the TEAD4 construct, immunostained, and imaged. Only after this process could embryos be genotyped, and only one quarter of them would be homozygous KOs. Taking into account the variability and mosaicism inherent to microinjection experiments, the number of mutant embryos that we would need to analyse in order to obtain a robust result would be large. We simply do not have the capacity, in terms of mouse space, funding and time, to carry out this experiment.

> 5\) Lack of clarity in the GOF and LOF regarding recombination events
>
> In the GOF and LOF experiments, the authors resort to immunostaining to identify the different cell recombination events. However, the GOF cells were triple positive because of antibody cross-reactivity. In addition, the images presented are unclear and, the examples given, fail to alleviate concerns about the validity of the approach and why it was used. If fixation reduced the fluorescence signal, could the embryos have been imaged live prior to that? Alternatively, have the authors attempted to validate their method by other means (by genotyping after immunostaining of individual dissociated blastomeres for example)? The fact that the less likely recombination event was observed the most often using this method adds to the concern that it may not accurately identify the right type of cell.

We agree with the reviewer that ideally using endogenous fluorescence single to follow the recombination events would have been best. Unfortunately, in this mouse line signal is too weak to observe directly, either in live embryos or fixed specimens. That is why we used immunostaining to distinguish different recombined cells. As for the reviewer's suggestion to genotype individual cells after immunostaining, although possible in principle, in our opinion it would result extremely challenging. First, dissociation of fixed cells from the embryos (as required for immunostaining) is difficult if not impossible without cross-contamination of neighbouring cells. And second, purification of DNA from this material would again be not that easy.

Nevertheless, the concern raised by the reviewer is valid, so we devised a way to independently test the panel of antibodies used to identify each different recombination event. For this, we used ES cells carrying the same construct, that were separated by FACS according to their fluorescence (fluorescence in cultured cells is bright enough to allow sorting). This is the same strategy used in the experiments described in Figure 6. We then tested all three antibodies (anti-CHERRY, -GFP and --HA) in each of the three sorted populations, finding the expected cross-reactivities: anti-CHERRY recognized the wildtype and gain-of-function recombined cassettes, anti-GFP the loss-of-function and the gain-of-function cassette, and anti-HA the gain-of-function cassette. We have included these results in the revised version in Figure 4---figure supplement 1A. As for the concern of the reviewer that the less likely recombination event was observed the most often, we have addressed this issue by including a new control experiment using an iChrControl-Mosaic line (see response to reviewer \#1 above, and Figure 4---figure supplement 3A-C).

> 6\) Number of independent biological replicates in RNA-seq experiments
>
> Only 2 Rbpj^-/-^ morulae were used in RNA-seq experiments. It seems unreasonable to justify this by the decision of wanting to strictly compare litter mates.

We have increased the sample size of *Rbpj*^-/-^ embryos analysed and repeated the analysis, reaching essentially the same conclusions as before (see response to reviewer \#1 above). Updated results are shown in Figure 5, Figure 5---figure supplement 1 and Figure 5---source data 1 and 2, as well as in the GEO database.

> 7\) Quantification of transient transgenic experiment
>
> Figure 5E-F -- It is not clear why the authors quantified positive and negative embryos. Unless I misunderstood the experiment, it seems that embryos injected with the mutated transcriptional enhancer should either drive H2B-mRFP weakly or not at all in comparison to the wild type construct. As a result, it seems that signal intensity should have been quantified instead.

We deeply apologize for the lack of clarity in the way we explain this set of experiments in the text, as the reviewer rightly points out. Reading again the original version, we can see how we took for granted certain methodological aspect that are far from clear and cannot be readily followed in the description we provide. We will try doing so in the following paragraph, as well as correcting the manuscript in order to provide a better explanation of the experiment.

In these transient transgenic experiments, each embryo is individually injected with the construct at the one-cell stage, allowed to develop to the desired stage (in this case, up to morula) and then scored for activity of the reporter. Because of the technique itself, embryos will be mosaic for the transgene, and we do not have control of the amount of construct received by an individual embryo, or even by different cells of the same embryo. Therefore, we cannot use signal intensity or number of positive cells as a reliable readout of construct activity. We thus score as positive any embryo that shows activity even in a single cell. When we use an empty vector (just the backbone of the minimal promoter plus the reporter), we obtain up to 10-15% of positive embryos. However, when testing fragments showing activity (such as the *Oct4* distal enhancer, or the *Cdx2* TEE), this proportion increases to 2-80%. Examples of this approach can be found in previous publications from our group (Pernaute et al. 2010, Dev Dyn 239 6209; Fernandez-Tresguerres et al. 2010, PNAS 107 19950-60; Rayon et al., 2014; Rayon et al. 2016, Sci Rep 6 27139). In the case of the *Tle4*-up genomic fragment, the wildtype construct drives expression in approximately 30% of microinjected embryos, and thus we consider it as a positive enhancer. However, when we mutate the putative RBPJ binding site only 13% embryos showed reporter activity. We therefore concluded that mutation of this sequence resulted in diminished enhancer activity. (Figure 5E, F) On the other hand, the *Tbx3*-i7 fragment drove reporter activity in 56% of embryos, what did not change significantly upon mutation of the putative RBPJ site (Figure 5---figure supplement 2B; C). In this case, we conclude that this genomic fragment does contain enhancer activity, but this is not dependant exclusively on the RBPJ site.

> 8\) CRISPR experiment
>
> Figure 5G -- Not enough information is provided to understand what mutations were obtained in the CRISPR experiment. Was a repair construct lacking the enhancer sequence introduced to generate a knockin in the endogenous locus? If not, were the different mutated embryos harbouring the same mutations?

We apologize once more for the lack of experimental detail provided in the original version of the manuscript. For these experiments, we used two gRNA flanking the putative RBPJ binding site, with the aim of generating deletion of approximately 150 bp in both cases. Due to the fact that each individual embryos needs to be processed for genotyping by PCR and expression analysis by RT-qPCR, we cannot obtain enough material to check in the same embryos the exact deletion generated. In order to provide more information on this point, we have carried out new deletion experiments, and in this case used the embryos for genomic DNA extraction, followed by PCR and cloning of the fragments of the expected size for the deletions. Sanger sequencing of individual clones shows that in the case of the deletion of the *Tle4*-up element, we recover two different deletions, and in the case of the *Tbx3*-i7 element three, all within the expected range. This data is now shown in Figure 5---figure supplement 2E, F, and we have corrected the text where necessary.

> Reviewer \#3:
>
> \[...\] The manuscript would benefit from some clarification regarding the role of Notch signalling in the exit of naive pluripotency. Specifically, it would be important to understand if Rbpj/Notch signalling is required for this process or if the regulation of Prdm14 and Dppa3 is reflecting other roles of Notch signalling. Therefore, it would be interesting to have a broader picture of the role of Notch in exit of pluripotency and if Tle4 is an important target during this process. Using naïve pluripotent ES cells (2i+Lif) and their differentiation will most likely be the most straightforward way to address this question.

This is a very interesting suggestion by the reviewer, so we repeated this experiment with ES cells grown in 2i+LIF. We observe the same trend as when using LIF+serum, in that Notch gain-of-function cells upregulated its putative targets *Tle4* and *Tbx3* following the same trend as established early epiblast markers (*Fgf5, Pou3f1* or *Otx2*). Interestingly, when we examined the expression of later differentiation markers such as *Eomes* or *Gata6*, we did not see any differences related to varying Notch activity. This suggests that Notch signalling is regulating early transition from naïve pluripotency, but not directly specific lineage differentiation events. We have now included these results in the text and present them in Figure 6---figure supplement 4.
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